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“…, but was engaged, heart and soul, in the pursuit of some discoveries which I hoped to 
make. None but those who have experienced them can conceive of the enticements of 
science. In other studies you go as far as others have gone before you, and there is nothing 
more to know; but in a scientific pursuit there is continual food for discovery and wonder.”1  
                                                 
1 Mary Shelley, “Frankenstein or, The Modern Prometheus”, 1818 
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INTRODUCTION 
 
The Paramyxoviridae family, order Mononegavirales, is divided into the Paramyxovirinae 
and Pneumovirinae subfamilies and includes several important pathogens of humans and 
animals (Table 1). The Pneumovirinae are further divided into the Pneumovirus and the 
Metapneumovirus genera. The classification of the two genera is based primarily on their 
gene constellation. Metapneumoviruses lack the nonstructural proteins NS1 and NS2, and the 
gene order is different from that of pneumoviruses (Pneumovirus: 3’-NS1-NS2-N-P-M-SH-G-F-
M2-L-5’; Metapneumovirus: 3’-N-P-M-F-M2-SH-G-L-5’; 93). Human respiratory syncytial virus 
(HRSV), the most prominent Pneumovirus, is the leading cause of serious lower respiratory 
tract infection in infants and young children worldwide. HRSV accounts for nearly one-
quarter of hospitalizations due to pediatric respiratory tract disease, and is associated with 
more than 100,000 hospitalizations annually of infants of less than one year of age in the 
United States (57). In addition, HRSV is increasingly recognized as an important disease in 
the elderly and in immunocompromised adults. Other members of the Pneumovirus genus 
include bovine respiratory syncytial virus (BRSV) which is the major etiological agent of 
respiratory disease in calves during their first year of life, ovine respiratory syncytial virus 
(ORSV), and pneumonia virus of mice (PVM). Avian pneumovirus (APV) and a newly 
discovered human pneumovirus (91) are the only members of the recently assigned 
Metapneumovirus genus.  
 
 
Table 1: The Paramyxoviridae family and its characteristic members 
 
 
Despite four decades of efforts, there are no effective means to control RSV infections. 
Treatment of children hospitalized with RSV is at most supportive, and the development of 
Subfamily Genus  Human Animal 
Paramyxovirinae Respirovirus Parainfluenzavirus types 1, 3 Sendai Virus 
 Rubulavirus Mumps virus 
Parainfluenzavirus types 2, 4 
Newcastle Disease Virus 
 Morbillivirus Measles virus Canine distemper virus 
Rinderpest virus 
Pneumovirinae Pneumovirus Human respiratory syncytial virus Bovine respiratory syncytial virus  
Pneumonia virus of mice 
 Metapneumovirus Human pneumovirus Avian pneumovirus 
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vaccines has been hampered by the lack of durable immunity, even after natural infection. 
Although effective passive immunoprophylaxis involving administration of RSV-neutralizing 
antibodies (palivizumab) is now available for high-risk individuals, RSV remains an 
important pathogen for vaccine development (41). 
 
 
1 RESPIRATORY SYNCYTIAL VIRUS 
 
Infectious agent  
 
RSV virions consist of a nucleocapsid contained within a lipid envelope and appear as 
irregular spherical particles that range in diameter from 150 to 300 nm in the electron 
microscope. The nucleocapsid is composed of the major nucleocapsid protein N, the 
phosphoprotein P, the antitermination factor M2-1, the large polymerase subunit L, and the 
negative-stranded RNA genome. Together they form a symmetrical helical ribonucleoprotein 
(RNP) complex.  
 
 
 
Fig. 1: Organization of a pneumovirus particle. Left: Electron micrograph of an animal pneumovirus 2. Right: 
A schematic pneumovirus particle: The RNP complex consists of the nucleocapsid protein N, the phosphoprotein 
P, the antitermination factor M2, the polymerase subunit L, and a single-stranded RNA genome of negative 
polarity. Three viral glycoproteins are incorporated into the lipid membrane, the fusion protein F, the 
glycoprotein G and the small hydrophobic protein SH. The matrix protein M forms an inner layer connecting the 
viral membrane with the RNP complex.  
                                                 
2 Taken from “The Big Picture Book of Viruses”; the image was kindly provided by Prof. Stewart McNulty, 
Queen’s University of Belfast, Copyright 1994 Veterinary Science Division  
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The envelope consists of a lipid bilayer derived from the host plasma membrane. It contains 
three virally encoded transmembrane surface glycoproteins, the attachment protein G, the 
fusion protein F, and the small hydrophobic SH protein. The viral glycoproteins are organized 
into virion “spikes” which are visualized as short, closely spaced surface projections. The 
matrix protein M is thought to form a layer on the inner envelope thereby connecting the 
nucleocapsid with the lipid bilayer (Fig. 1).  
 
 
The genome  
 
Infectious RSV contains a nonsegmented, single-stranded RNA genome of negative polarity 
tightly contained in an RNase resistant nucleoprotein complex. Antigenomic RNA, the 
intermediate in RNA replication, is an exact complementary copy of genomic RNA. Both 
RNAs are neither capped nor polyadenylated.   
 
RSV encodes 10 major subgenomic mRNAs (Fig. 2). Each contains a single open reading 
frame (ORF) except for M2, which contains the M2-1 and M2-2 ORFs. All mRNAs are 
capped at the 5’-end and polyadenylated at the 3’-end. Both modifications are thought to be 
mediated by the viral polymerase. Each gene begins with a 10-nucleotide gene-start (GS) 
signal that is highly conserved and terminates with a semiconserved 12 to 13 nucleotide (nt) 
gene-end (GE) signal that directs polyadenylation and release of the completed mRNA. The 
first nine RSV genes are separated by intergenic regions that range in length from 1 to 56 
nucleotides and are not well conserved among strains. The last two RSV genes, M2 and L, 
overlap by 68 nucleotides leaving the GS signal of the L gene within, rather than downstream 
of, the M2 gene. The 3’-ends of genomic (leader, 44 nt) and antigenomic (trailer, 155 nt) 
RNA are 81% identical for the first 26 nucleotides, probably representing the major element 
of a conserved promoter (74). 
 
 
Fig. 2: Genome organization of RSV. The location of transcripts (mRNA; shaded bars) and protein-encoding 
frames (open bars) are shown relative to the viral genome (vRNA; solid bar). 
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Viral proteins  
 
The RSV fusion protein F is a transmembrane glycoprotein responsible for virus penetration 
and syncytium formation. Like other paramyxovirus F proteins, RSV F appears to form 
trimers. It is synthesized as the precursor F0 that is cleaved by cellular proteases in the trans-
Golgi network to yield the disulfide- linked heterodimer F2-F1. This cleavage liberates the 
hydrophobic “fusion peptide” at the N-terminus of the F1 subunit which is thought to be 
directly involved in target membrane insertion. Together with the glycoprotein G, the fusion 
protein is the major protective antigen of RSV and only antibodies against F or G neutralize 
infectivity in vitro and confer resistance to RSV infection when transferred passively to 
experimental animals (86,95). Furthermore, the fusion protein was found to mediate T cell 
cycle arrest by contact in a species-specific manner, hinting at an immunosuppressive activity 
of RSV (81). 
 The glycoprotein G was described as the major RSV attachment protein because 
antibodies specific to G blocked the binding of virions to HeLa cells, whereas antibodies 
against F prevented fusion but not binding. G is a type II transmembrane glycoprotein heavily 
glycosylated with N- and O-linked sugars. G assembles into homo-oligomers that probably 
are trimers or tetramers. In addition, a truncated, soluble G protein is expressed from the G 
mRNA arising from translational initiation at the second AUG in the ORF. The significance 
of this form is unclear, although it might function as a decoy to trap RSV-neutralizing 
antibodies and might influence the immune response. Remarkably, the G protein is not 
essential for virion assembly and propagation in vitro or in vivo, although in most cases, it 
enhances virus multiplication (74).  
 The small hydrophobic SH protein is a short integral membrane protein with unknown 
function. SH accumulates in multiple glycosylated and nonglycosylated forms. All forms 
associate into oligomers. Recombinant RSV from which the SH gene has been deleted is fully 
viable in vitro and in vivo. Expression of the SH protein in bacteria increased cell 
permeability for small-molecular-weight compounds suggesting that the SH protein forms 
membrane channels (73). However, it is unclear what role such an activity would play for 
RSV. 
 The matrix protein M is a nonglycosylated inner virion protein. M plays an important 
role in the formation of virus- like particles by mediating the association of the nucleocapsid 
with the nascent envelope. A hydrophobic domain in the C-terminal half of the molecule 
might be responsible for the interaction with membranes (74). 
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 The RSV N, P, and L proteins copurify with nucleocapsids. The nucleoprotein N binds 
tightly to genomic and antigenomic RNA to form an RNase-resistant nucleocapsid. The 
phosphoprotein P appears to function as a chaperonin for soluble N. In addition, soluble N 
and P form stable complexes that can be immunoprecipitated. P also functions as a 
polymerase cofactor and must be phosphorylated to be functional. A polymerase reconstituted 
with unphosphorylated P produced a series of short oligonucleotide transcripts from the 3’-
end of the genome suggesting that phosphorylated P protein is necessary to convert newly 
initiated polymerase into a stable complex (30). The RSV L protein is the major subunit of the 
RNA-dependent RNA polymerase. It contains six discrete segments that contain highly 
conserved residues that presumably represent polymerase motifs. N, P, and L are the viral 
proteins necessary and sufficient for RNA replication. N, P, and L can also direct 
transcription, but full processivity requires in addition the M2-1 protein. M2-1 is encoded by 
the 5’-proximal ORF of the M2 mRNA and functions as a transcription antitermination factor 
essential for viral viability. M2-1 can bind to N and colocalizes with N and P in cytoplasmic 
inclusion bodies (74). 
 The M2-2 protein is expressed from the M2 mRNA by a translational termination-
reinitiation mechanism. A recombinant virus lacking the M2-2 gene displayed increased 
transcription and reduced replication compared to the wildtype indicating a possible role for 
M2-2 in regulating RNA synthesis (6,51). 
  The nonstructural proteins NS1 and NS2 are detected in only trace amounts in 
preparations of purified virions and are therefore considered nonstructural. Due to their 3’ 
proximal location, they are abundantly expressed in infected cells. Deletion of NS1 or NS2 
renders RSV viable but attenuated in vitro and in vivo (8,52,87,88). Studies using a 
minigenome system revealed an inhibitory effect of NS1 on transcription and RNA 
replication suggesting a role, at least for the NS1 protein, in RNA synthesis (3). 
 
 
Replicative cycle 
 
Attachment of the virion is probably initiated by binding of the RSV G protein to certain 
cellular glycosaminoglycans (GAGs) found in the extracellular matrix followed by a second 
binding step involving one or more of the three RSV surface proteins. However, a 
recombinant RSV lacking the G and SH genes can multiply efficiently in vitro implying that 
the remaining surface protein F alone can mediate attachment. Nevertheless, although G is 
dispensable in vitro, it is clearly important for efficient infection in vivo.  After successful 
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attachment, RSV enters the cell by fusion at the plasma membrane rather than by endocytosis. 
Viral penetration is entirely mediated by the fusion protein F which directs the fusion between 
the virion envelope and the host cell plasma membrane, thereby delivering the nucleocapsid 
to the cytoplasm. From there on, all events in the RSV replicative cycle occur in the 
cytoplasm, apparently without nuclear involvement. RSV infection results in the formation of 
dense cytoplasmic inclusions that appear to consist mainly of nucleocapsids. Later in 
infection, the increasing amount of F protein expressed on the cell surface can mediate fusion 
with neighboring cells, leading to the formation of syncytia. 
 Intracellular replication begins with the viral RNA-dependent polymerase complex 
transcribing the genome into 5’-capped and 3’-polyadenylated mRNAs. The viral polymerase 
complex starts all RNA synthesis at the 3’ end of the genome transcribing the genes into 
mRNAs in a sequential manner by terminating and reinitiating at each of the gene junctions. 
The junctions consist of a gene-end signal at which polyadenylation occurs by the reiterative 
copying of four to seven uridylates followed by the release of the mRNA. Then follows a 
short nontranscribed intergenic region, and a gene-start signal that specifies capping as well as 
mRNA initiation. The polymerase complex occasionally fails to reinitiate the downstream 
mRNA at each gene junction, leading to the loss of transcription of further downstream genes. 
This results in a gradient of mRNA synthesis that is inversely proportional to the distance of 
the gene from the 3’ end of the genome (78). Only after translation of the primary transcripts 
and accumulation of the viral proteins, antigenome synthesis begins. Here, the polymerase 
complex copies the same template but it now ignores all the junction signals and synthesizes 
an exact, complementary copy. Genome synthesis from antigenome templates is thought to 
take place in a fashion similar to that of antigenome synthesis, starting at the 3‘ end of the 
antigenome. Antigenomic RNA, the positive-sense replicative intermediate, is 10- to 20-fold 
less abundant than genomic RNA. Both RNAs are present in virion preparations in this same 
proportion indicating a lack of discrimination in packaging. The synthesis of genomic and 
antigenomic RNA is dependent on ongoing protein synthesis, probably reflecting a need for 
cosynthetic encapsidation. For paramyxoviruses, the availability of N needed for cosynthetic 
encapsidation is thought to be responsible for the switch from transcription to RNA 
replication. However, studies using a recombinant RSV lacking the M2-2 open reading frame  
suggest that, during replication of RSV, the intracellular concentration of M2-2 is involved in 
this switch (78,6).  
 Assembly of nucleocapsids takes place in the cytoplasm and is believed to occur in two 
steps. First, free N associates with the genome or antigenome RNA forming a helical RNP 
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structure. Secondly, P-L protein complexes associate with the nucleocapsid. RSV virion 
maturation occurs at the cell surface where progeny virions acquire a lipid envelope enriched 
in viral surface glycoproteins by budding at the plasma membrane. M proteins are thought to 
play a major role in bringing the assembled RNP to the appropriate patch on the plasma 
membrane to form a budding virion. The protein-protein interactions involved in assembling a 
virion must be specific, as cellular membrane proteins are largely excluded from the virions. 
It is presumed that the glycoprotein cytoplasmic tails make important contacts with the M 
protein layer which, in turn, associates with the nucleocapsid. However, the efficient 
replication in vitro of DSHDG recombinant RSVs indicates that F is the only viral 
transmembrane protein required for efficient virion formation. Disruption of cellular actin 
filaments drastically reduce the production of infectious virus implying a role for the 
cytoskeleton in assembly (12). 
 
 
Epidemiology 
 
RSV is the single most important cause of respiratory tract infections in infants and young 
children worldwide and is believed to account for approximately 85% of cases in bronchiolitis 
and approximately 20% of cases of childhood pneumonia (103). It infects the very young 
infant and the neonate despite the presence of maternally derived antibodies, and infection 
and reinfection are frequent during the first few years of life. Reinfection of adults is also 
common, particularly when exposure to virus is heavy. In addition, RSV is a pathogen of 
considerable importance in the elderly. RSV has a worldwide distribution and shows clear 
seasonality in temperate zones of the world. In urban centers, epidemics occur yearly in the 
late fall, winter or spring but not during the summer. Each RSV epidemics lasts 
approximately 5 months, with 40% of infections occurring during the peak month in the 
temporal center of the outbreak. It is not known why the virus disappears in the spring, nor 
from where it reemerges in the fall or winter. In the United States, RSV was recently 
estimated to be responsible for 73,400 to 126,300 hospitalizations annually for bronchiolitis 
and pneumonia alone among children younger than 1 year (84). Bronchiolitis or pneumonia 
occurs most frequently between ages 6 weeks and 9 months, whereas the peak incidence of 
lower respiratory disease is between ages 2 and 7 months corresponding with diminishing 
titers of maternal antibodies. The risk of serious RSV disease is increased by prematurity, 
young age, chronic cardiac or lung disease, immunodeficiency or immunosuppression, or 
familiy history of allergic disease. However, approximately three fourths of hospitalizations 
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for RSV disease occur in infants and children who were previously healthy. However, 
mortality due to RSV infection is not common in developed countries (74). 
 
 
Pathogenesis and immunity 
 
Spread of RSV occurs by direct inoculation of contagious secretions from the hands or by 
large-particle aerosols into the eyes and nose, but rarely the mouth. After an incubation period 
of two to eight days, RSV replicates in the nasopharyngeal epithelium, with spread to the 
lower respiratory tract one to three days later. Pathological characteristics of severe RSV 
infection are necrosis and proliferation of the bronchiolar epithelium and destruction of 
ciliated epithelial cells (68). A peribronchiolar infiltrate of lymphocytes, plasma cells and 
macrophages develops, with migration of the lymphocytes among the mucosal epithelial cells. 
Edema develop and secretion of mucus increases, obstructing the bronchioles and alveoli. In 
cases of pneumonia, alveolar spaces may fill with fluid and mononuclear cells infiltrate the 
interstitium. Immunostaining of infected lungs showed virus-infected cells in the bronchial, 
bronchiolar, and alveolar epithelium, and identified numerous syncytial cells (68). Direct 
virus-mediated cytopathology and the local inflammatory response initiated by RSV infection 
also contributes to RSV pathogenesis, resulting in considerable damage to the epithelium and 
to the bronchiolar ciliary apparatus. Complete restoration requires four to eight weeks, in 
correlation with the common clinical findings of prolonged cough, wheezing, and altered 
pulmonary function (42,74). 
 
RSV is unusual in its ability to infect infants in the presence of moderate titers of 
maternal antibodies and to readily reinfect persons of all ages. Naturally acquired immunity is 
neither complete nor durable, making the development of an effective vaccine more difficult. 
Nevertheless, protection against severe disease develops after primary infection.  
The adaptive immune system has the primary role in recovery from RSV infection and 
resistance to reinfection (23). For example, immunodeficient children fail to clear RSV, and 
severely immunocompromised adults, such as bone marrow transplant recipients, have a very 
high incidence of RSV infection leading to serious disease and death (46).  
In the BALB/c mouse model, pulmonary NK cells appear in the first few days after 
RSV infection followed by pulmonary CD8+ cytotoxic T cells (CTLs) and secretory 
antibodies. In addition to being direct effectors against virus- infected cells, NK and CD8+ T 
cells modulate the immune response by secretion of lymphokines, especially IFN-g (74). 
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Studies in which the CD4+ and CD8+ T- lymphocyte subsets were depleted individually or 
together demonstrated that both are important for clearing a primary infection (39). Studies in 
which mice were depleted of B lymphocytes showed that RSV-specific antibodies are not 
required for virus clearance during a primary infection, but are very important in restricting 
replication and disease on reinfection (38). Immunization of BALB/c mice with recombinant 
vaccinia viruses that express individual RSV proteins showed that F and G are the only viral 
proteins that induce RSV-neutralizing antibodies and long- lived resistance to reinfections 
with RSV (21). The secretory antibodies produced by infants in response to RSV infection 
often fail to neutralize the virus in vitro (65), and this defect may be at least partially 
responsible for the incompleteness of natural immunity after infection during infancy and 
early childhood. In older individuals, multiple reinfections induce higher levels of IgA 
antibodies. Experimental infections of adult volunteers have shown that immunity to infection 
correlates better with the level of nasal RSV-neutralizing IgA antibodies than with serum 
RSV-neutralizing antibodies (74). To completely eliminate RSV, CD8+ CTLs appear to be 
required. However, studies in mice also provide evidence that RSV-specific CTLs may play a 
role in the pathogenesis of RSV disease. Passively transferred, stimulated RSV-specific CD8+ 
CTLs clear virus from the lungs of persistently infected, gamma-irradiated mice. Similarly, 
CD8+ CTLs accelerate clearance of RSV from the lungs of infected immunocompetent mice, 
but clearance is accompanied by acute pulmonary disease (74). These observations suggest 
that a balance exists between the protective and disease-producing effects of CD8+ CTLs. 
 
 
 
2 THE INTERFERON-a/b  SYSTEM 
  
Interferons (IFNs) are a large family of multifunctional secreted proteins involved in antiviral 
defense, cell growth regulation and activation of the immune system. Type I IFNs (IFN-a and 
IFN-b) are produced in response to viral infection, double stranded RNA (dsRNA) or tumor 
necrosis factor (TNF-) a. Whereas products of the IFN-a multigene family are predominantly 
synthesized by leukocytes, IFN-b  is produced in most cell types, particularly by fibroblasts. 
The expression of the type II IFN gene, IFN-g, is restricted to activated T lymphocytes and 
natural killer (NK) cells. Both types of IFN share no obvious structural homology but a 
functional similarity exists due to an extensive overlap in the set of genes they induce. The  
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importance of IFN in mediating responses to viral infections is demonstrated by the fact that 
mice lacking IFN receptors are unable to mount effective immune responses to a large 
number of different viruses. Both types of IFN stimulate an antiviral state in target cells 
whereby replication of the virus is blocked or impaired due to the synthesis of a number of 
enzymes that interfere with cellular and viral processes or due to the elimination of the 
infected cell via the apoptotic pathway. In addition, both types of IFN possess extensive 
immunomodulatory functions, albeit with different specificities, affecting nearly all phases of 
the innate and adaptive immune response (37).  
 
 
Virus induction of IFN genes 
 
Induction of IFN gene transcription is tightly regulated by extra- and intracellular signals 
induced at the site of infection. One of the best characterized models of such regulation is the 
IFN-b  gene promoter/enhancer. This promoter contains an overlapping set of regulatory 
elements designated positive regulatory domains (PRDs) I to IV which interact with several 
signal-responsive transcription factors including NF-kB, ATF/c-Jun heterodimers, and 
interferon regulatory factor 3 or 7 (IRF-3/7) that bind to PRD II, PRD IV, and PRD I-III, 
respectively. Together with the chromatin-associated HMG I(Y) proteins, these transcription 
factors form a transcriptional enhancer complex, termed the enhanceosome, that stimulates 
the high level, transient activation of IFN-b  transcription (Fig. 3; 83).  
The pathways involved in NF-kB and AP-1 (ATF-2/c-Jun) activation are well 
characterized. Following viral infection, treatment with proinflammatory stimuli like TNF-a, 
or exposure to dsRNA, these transcription factors are activated through stimulation of distinct 
kinase cascades. In uninfected cells, NF-kB is retained in the cytoplasm in association with 
inhibitory subunits termed IkBs. Upon viral infection, IkB is phosphorylated at conserved 
residues by the IkB kinase (IKK) complex leading to ubiquitin-dependent degradation of IkB 
and subsequent nuclear translocation of NF-kB (26). Activation of the IKK complex is 
thought to be mediated by the dsRNA-dependent protein kinase (PKR) which activates the 
IKKb  subunit of the multicomponent IkB kinase (110). PKR can also phosphorylate IkB 
directly (58). However, the biological role for this is unclear. Unlike NF-kB, the heterodimers 
ATF-2/c-Jun are expressed as nuclear proteins that are activated by phosphorylation of their 
activation domains by c-Jun amino-terminal kinases (JNKs) which are downstream of a well 
defined stress-activated kinase cascade (100). 
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The pathways regulating IRF-3 phosphorylation and activation are under intense 
investigation. IRF-3 belongs to the family of interferon regulatory factors (IRFs; 62) and is 
expressed constitut ively in a variety of tissues. The relative levels of IRF-3 mRNA do not 
change in virus- infected or IFN-treated cells. IRF-3 demonstrates a unique response to viral 
infection. Phosphorylation of latent cytoplasmic IRF-3 on serine and threonine residues in the 
C-terminal region leads to a conformational change, dimerization, cytoplasmic to nuclear 
translocation, association with the p300/CBP coactivator and transcriptional activity. The 
rate- limiting step in this process is the C-terminal phosphorylation of IRF-3 by an as of yet 
uncharacterized virus activated kinase (VAK) activity (83). 
 
 
 
Fig. 3: Transcriptional induction of the IFN-b gene. Virus infection and dsRNA generated during viral 
replication are able to activate Jun kinases (JNKs), PKR, and perhaps other cellular kinases. PKR in turn 
activates the IkB kinase leading to the activation of NF-kB. ATF-2/c-Jun and NF-kB, together with a member of 
the IRF family, assemble on the IFN-b promoter with the help of the accessory factor HMG-I/Y to form a 
complex called the ‘enhanceosome’. This complex then interacts with factors of the basal transcription 
machinery resulting in transcription of the IFN-b gene. 
 
 
The trigger for IRF-3 activation is generally believed to be dsRNA. Indeed, RNA viruses such 
as Newcastle disease virus (NDV), Sendai virus (SeV) or vesicular stomatitis virus (VSV) are 
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potent inducers of VAK activity as is the synthetic dsRNA analog polyI/C. However, 
tenOever et al. recently demonstrated that the expression of a viral protein, the Measles virus 
(MeV) nucleocapsid protein, was sufficient for IRF-3 activation (89). DNA viruses, in 
particular herpes simplex virus 1 (HSV-1) and human cytomegalovirus (HCMV), were also 
reported to activate IRF-3. Interestingly, whereas binding of HCMV to its cellular receptor 
was sufficient to trigger IRF-3 activation, entry of virus particles but not de novo transcription 
of viral genes was necessary to activate IRF-3 in the case of HSV-1 (76). Recently, the Rho 
GTPases Rac-1 and RhoA were identified to be specifically involved in virus induced gene 
expression from IRF-3 responsive promoters since specific inhibitors or dominant negative 
forms inhibited virus or dsRNA induced activation of the IFN-b  promoter (32). Further 
studies will shed more light on the different mechanisms by which cells are able to recognize 
viral infections, leading to the activation of IRF-3 and the subsequent establishment of an 
antiviral state.  
 
 
Signal transduction in response to IFNs 
 
The type I IFN receptor is composed of two major subunits, IFNAR1 and IFNAR2. Binding 
of IFN-a/b  leads to the association of IFNAR1 and IFNAR2, thereby facilitating the 
activation of the receptor-associated janus tyrosine kinases, Jak1 and Tyk2, which in turn 
activate by phosphorylation the ‘signal transducers and activators of transcription’ STAT1 
and STAT2 (37). The phosphorylated STAT1/STAT2 heterodimers thus formed dissociate 
from the receptor and trans locate into the nucleus. In the nucleus they associate with the 
DNA-binding protein IRF-9 (p48) to form a complex called ISGF3 which binds to specific 
DNA sequences containing ‘interferon stimulated response elements’ (ISRE) and promotes 
the transcription of downstream genes (Fig.4; 94). Approximately 300 genes are known to be 
transcriptionally stimulated by type I IFNs (27). Among these genes, those encoding the 
dsRNA-dependent protein kinase (PKR), the 2’5’-oligoadenylate synthetases, and the Mx 
proteins are known to interfere with viral replication by different mechanisms. In this manner, 
virus- induced secretion of type I IFNs contributes to the induction of an antiviral state in 
neighboring, uninfected cells.  
Attenuation of IFN signaling is achieved by several mechanisms. Downregulation of 
activated STAT1 is mostly due to dephosphorylation by a tyrosine phosphatase (44). In 
addition, STAT1 is turned over by a mechanism involving proteasome-mediated degradation. 
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Moreover, several IRF proteins are known to bind ISREs and negatively regulate expression, 
probably preventing expression in the absence of IFN. Also, IFN-induced proteins may play a 
role in regulating IFN signaling, i.e. the SOCS/JAB/SSI family induced by IFN-g was shown 
to bind and inhibit activated Jaks, leading to signal downregulation (37). 
 
Fig. 4: Signaling pathways activated by IFN-b. Binding of IFN-b to its receptor activates receptor-associated 
kinases that phosphorylate members of the STAT family of transcription factors which can then enter the 
nucleus. In combination with p48, they bind to the ISRE element of target genes and activate their transcription. 
 
 
The antiviral response 
 
The best-characterized IFN-inducible components of the antiviral response are PKR, the 2’-5’ 
oligoadenylate synthetases, and the Mx proteins. The RNA-dependent protein kinase PKR is a 
serine/threonine kinase with multiple functions in control of transcription and translation. The 
PKR protein has two known domains, an N-terminal dsRNA binding site and a C-terminal 
catalytic domain that shows protein kinase activity. PKR is activated by binding dsRNA, and 
the active form is postulated to be a dimer with two PKR molecules binding one molecule of 
dsRNA. These juxtaposed PKR molecules are then able to phosphorylate each other on 
several residues. There are no sequence requirements for the dsRNA. However, there are at 
least 50 base pairs of duplex necessary for activation. Activated PKR phosphorylates the a 
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subunit of the eukaryotic translation initiation factor eIF2, thereby leading to a shut-down of 
protein translation. Phosphorylated eIF2a interacts strongly with the guanine exchange factor 
eIF2B which, in turn, cannot mediate the recycling of eIF2-GDP to eIF2-GTP. Since eIF2B is 
present in limiting amounts, translation is inhibited (16). PKR also plays a role in mediating 
signal transduction events in response to dsRNA and other ligands (102), and in mediating 
apoptosis. The downstream targets for PKR-mediated apoptosis remain to be identified but 
overexpression of PKR has been shown to induce apoptosis through a Bcl2- and caspase-
dependent mechanism (60). 
 2’-5’ oligoadenylate synthetases are a group of enzymes that, once activated by binding 
to dsRNA, catalyse the synthesis of adenosine oligomers from ATP that are linked by 
phosphodiester bonds in the unusual conformation of 2’ to 5’ (2’5’A). The 2’5’A molecules 
bind to endoribonuclease L (RNase L) and induce its activation via dimerization (37). 
Activated RNase L then catalyses the cleavage of single-stranded RNA including mRNA and 
rRNA leading to inhibition of protein synthesis. Since 2’5’A is highly labile, the activation of 
RNase L depends upon locally activated 2’-5’oligoadenylate synthetases, thus ensuring that 
virus transcripts are destroyed preferentially over cellular mRNAs. 
 Mx proteins are highly conserved, large GTPases with homology to dynamin, and they 
were found in all vertebrate species examined so far (72). Mx proteins are known to impair 
the growth of a wide range of RNA viruses, probably at the level of virus transcription or 
replication. Recently, Kochs et al. reported that MxA binds to the nucleocapsid protein N of 
La Crosse Virus (LACV) and aggregates it into large complexes. Thus, by trapping this 
essential virus component in cytoplasmic inclusions viral replication is inhibited (56).  
Studies involving the generation of triple knockout mice lacking PKR, RNAse L and 
Mx1 indicate that there are additional antiviral effects of IFNs (111). Other factors that clearly 
play a role are caspases and the dsRNA-dependent adenosine deaminase (ADAR; 71). In 
addition, further functions of IFNs such as their antiproliferative activity, immunomodulatory 
function and ability to control apoptosis also contribute to the successful elimination of viral 
infections. 
 
 
Viral countermeasures to the IFN response 
 
To successfully establish infections in vivo, viruses must replicate in the face of antiviral 
defense mechanisms induced by IFNs. It therefore seems likely that all viruses must, at least 
to a certain extent, have some means of circumventing or blocking the IFN response. 
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However, viral countermeasures rarely achieve absolute inhibition, and the IFN response, by 
limiting virus spread, buys time for the generation of an acquired immune response to the 
invading virus. On the other hand, the speed and efficiency of the virus in circumventing the 
action of IFN may be critical to its host range and pathogenicity. 
Viruses vary considerably in their ability to induce IFN. This may simply reflect the 
amount of dsRNA produced during infection or the inability of the cell to detect certain viral 
infections. However, it may also indicate that viruses are able to inhibit the induction of IFN. 
Several viruses have been reported to encode dsRNA-binding proteins, e.g. the reovirus major 
outer capsid protein s3 (5), the NS1 protein of influenza virus (35), the E3L protein of 
vaccinia virus (14) as well as the NSP3 gene products of porcine rotavirus (59) were shown to 
bind dsRNA. Sequestration of dsRNA may prevent IFN-a/b  production, thereby minimizing 
the dsRNA-dependent activation of antiviral gene products such as PKR, 2’-5’ oligoadenylate 
synthetases, or ADAR. Another common strategy to block IFN-a/b  production is to target the 
activity of transcription factors necessary for IFN-b  promoter induction. African swine fever 
virus (ASFV) encodes a homologue of IkB that inhibits the activity of NF-kB (77) whereas 
human herpesvirus 8 (HHV-8) encodes a viral IRF-1 homologue that blocks the formation of 
transcriptionally competent IRF-3-CBP/p300 complexes (112). The E6 protein of human 
papillomavirus type 16 (HPV-16) binds IRF-3 and can inhibit its transcriptional activity (79). 
However, induction of IFN-b  is never blocked completely, suggesting that other factors can 
substitute functionally for IRF-3. These potential substitutes include IRF-1 and ISGF3, but 
these factors themselves can be targeted by viral proteins. The plethora of factors that can 
bind and activate the IFN-b promoter probably reflects a pivotal need of the cell to be able to 
circumvent viral blockades. 
 
Blocking of the IFN signaling pathway can occur at several levels, and there is accumulating 
evidence that viruses are able to block most, if not all, stages. Several poxviruses have been 
shown to encode soluble IFN-receptor homologues that bind and sequester IFNs to prevent 
their biological activity. Inside the cell, human cytomegalovirus (HCMV) inhibits the 
phosphorylation of STATs by decreasing the levels of Jak1 and IRF-9 (p48) by a mechanism 
involving the proteasome (67) whereas the T antigen of murine polyomavirus (MPyV) binds 
to and inactivates Jak1 (99). Further downstream in the signaling cascade, the V protein of 
simian virus 5 (SV5) and mumps virus (MV) target STAT1 for proteasome-mediated 
degradation (29,105) whereas human parainfluenza virus 2 (hPIV2) targets STAT2, thereby 
preventing the formation of ISGF3 complexes (108). Interestingly, at least part of the host 
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range of SV5 appears to be determined by the ability to mediate STAT1 degradation (107). 
The adenovirus E1A protein decreases STAT1 and IRF-9 levels, and sequesters the 
transcriptional coactivator CBP/p300 (61). Furthermore, the E7 protein of HPV-16 interacts 
directly with IRF-9, preventing the formation of ISGF3 and thus the activation of IFN-a/b-
inducible genes (4). It has also been reported that EBNA2 of Epstein-Barr Virus (EBV) 
inhibits IFN-a/b  signaling by an unknown mechanism that does not prevent the formation of 
ISGF3 complexes (53). The block in IFN signaling is advantageous since it prevents the 
induction of antiviral genes and the upregulation of class I MHC molecules within infected 
cells, making them poorer targets for cytotoxic T cells. In addition, since there are 
components in common between IFN-a/b  and IFN-g signaling pathways, it is possible for a 
virus to block either one or both pathways. However, it was recently reported that IRF-3 is not 
only involved in the induction of the immediate early IFN-a/b  genes but also in the direct 
activation of a subset of antiviral IFN-stimulated genes, adding to the complexity of the 
cellular IFN system encountered by viruses (40). 
Another major strategy to overcome the antiviral state is the inhibition of IFN-induced 
antiviral enzymes. The importance of PKR in the establishment of antiviral activity can be 
inferred from the wide variety of mechanisms that are employed by viruses to inhibit its 
activity. Since dsRNA is required to activate PKR, viruses that encode dsRNA-binding 
proteins, e.g. influenza virus NS1 and vaccinia virus E3L, simultaneously inhibit both IFN 
induction and PKR activation. In addition to binding dsRNA, viral gene products can inhibit 
PKR in several other ways. For example, poliovirus induces the degradation of PKR whereas 
the nonstructural protein NS5A of hepatitis C virus (HCV) or the baculovirus PK2 protein 
bind PKR directly and inhibit its activity (37). The K3L gene product of vaccinia virus has 
structural similarity to the N terminus of eIF2a and binds tightly to PKR, preventing its 
autophosphorylation and subsequent activation (24). A more indirect method of coping with 
PKR is illustrated by the g1 ICP34.5 protein encoded by herpes simplex virus (HSV). ICP34.5 
interacts with the cellular protein phosphatase 1a (PP1) redirecting it to dephosphorylate, and 
hence reactivate, eIF2a (45). Moreover, some viruses abundantly produce short RNA 
molecules, e.g. the adenovirus VAI transcripts, that bind avidly to the dsRNA-binding site of 
PKR and act as competitive inhibitors of PKR activation by dsRNA. Another target for viral 
gene products is the 2’-5’ oligoadenylate synthetase/RNase L system. HIV-1 (63) and 
encephalomyocarditis virus (EMCV) (64) downregulate RNase L activity by inducing the 
expression of the RNase L inhibitor RLI which antagonizes the binding of 2’5’A to RNase L, 
thus preventing its activation. Since dsRNA is also required for the activation of RNase L, 
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virus proteins that sequester dsRNA are able to inhibit both PKR and the 2’-5’ oligoadenylate 
synthetase/RNase L system. 
 
 
3 THE NONSTRUCTURAL PROTEINS NS1 AND NS2 
 
Overview 
 
The nonstructural proteins NS1 and NS2 (formerly 1C and 1B, respectively) are present in 
only trace amounts in partially purified HRSV virions (48) and are therefore considered to be 
nonstructural proteins. Interestingly, both genes are present in the genomes of the four 
mammalian members of the Pneumovirinae, human RSV, bovine RSV, ovine RSV, and 
pneumonia virus of mice, and are located at the 3’ end of the genome between the 
untranslated leader region and the nucleoprotein gene. The nucleotide sequences and  deduced 
amino acid sequences have been determined for all pneumovirus NS protein genes. The 
HRSV subgroup A NS1 and NS2 genes are 528 and 499 nucleotides (nt) long with single 
open reading frames (ORF) encoding polypeptides of 139 and 124 amino acids, respectively 
(19). Similarly, the NS1 and NS2 genes of BRSV strain A51908 are 524 and 489 nt long and 
encode polypeptides of 136 and 124 amino acids, respectively (70). Comparison of the NS1 
gene of BRSV with corresponding sequences of HRSV subgroup A revealed 69% identity at 
the amino acid level (Fig. 5). The predicted amino acid identity for the NS2 gene was 84%. 
The NS1 and NS2 genes of PVM consist of 410 and 571 nucleotides and encode proteins of 
113 and 156 amino acids, respectively (13). Both proteins show only low sequence homology 
to their counterparts in HRSV (Fig. 5). Database searches with the pneumovirus NS proteins 
did not reveal any homology to known proteins, neither were domains identified that would 
hint at a possible function for the NS proteins in the viral life cycle.  
 
Given the progressive attenuation of transcription characteristic for non-segmented negative 
strand RNA viruses, the 3’ location of the NS1 and NS2 genes ensures that the transcripts of 
these genes are the most abundant of the ten RSV mRNAs (18). Consequently, the NS1 and 
NS2 proteins are expected to be highly expressed in infected cells. However, monoclonal 
antibodies capable of recognizing the NS1 and NS2 proteins have not been described, 
suggesting that they are of low immunogenicity during natural infection. Indeed, three human 
convalescent sera from individuals that had been infected with RSV showed no reaction with 
          INTRODUCTION  
     18 
NS1 and NS2 (33). Furthermore, vaccinia virus recombinants expressing the NS proteins did 
not confer protective immunity in mice when challenged with live RSV (21), and no murine 
helper T cell response to NS2 was elicited by a recombinant vaccinia/NS2 virus (69). 
However, a cytotoxic T cell response to the NS2 protein was observed in six of nine human 
adult volunteers, but only one of the same nine volunteers reacted to the NS1 protein (15).  
 
 
 
 
Fig. 5: Amino acid sequence comparison of pneumovirus NS proteins. Amino acids identical in all three 
proteins are marked by black bars. Amino acid identical between two proteins and amino acid similarities are 
marked in gray.  
 
 
The first study aimed at elucidating the function of the nonstructural proteins in the viral life 
cycle was published in 1995. Here, Yu et al. demonstrated that neither HRSV NS protein is 
required for RNA replication in a helper- independent in vitro system (109). It was further 
shown that both HRSV NS proteins are synthesized early in infection and are present in 
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multimeric forms in infected cells (33). The HRSV NS1 protein has been shown to 
coprecipitate with the matrix protein (33) whereas the HRSV NS2 protein colocalizes in cells 
with the N protein (98) but does not coprecipitate with any viral protein. In addition, the 
HRSV NS2 protein is unstable with a half life of approximately 30 minutes (33). In a HRSV 
minigenome system complemented by plasmid-encoded support proteins, coexpression of 
HRSV NS1 cDNA strongly inhibited transcription and RNA replication mediated by the RSV 
polymerase even at very low expression levels suggesting a role for the NS1 protein in RNA 
synthesis (3).   
 
 
Reverse genetics as a tool to study viral gene function 
 
The development of a reverse genetic system by which complete infectious recombinant 
negative-stranded RNA virus can be recovered from cDNA has provided a new and powerful 
tool for the experimental analysis of viral gene functions with molecular approaches (22). 
Successful recovery of negative-strand RNA viruses requires the intracellular reconstitution 
of RNP complexes from plasmid-derived components. Simultaneous production of full- length 
antigenomic RNA and of individual RNP-associated proteins by transfection of cells with 
appropriate expression plasmids results in the initiation of an infectious cycle and the 
recovery of recombinant virus, as was shown first for rhabdoviruses (82). Whereas the N, P 
and L proteins and full- length antigenome RNAs are sufficient to obtain infectious 
rhabdovirus and most paramyxoviruses, efficient recovery of recombinant RSV also requires  
the expression of the M2 gene (8,10). Using the reverse genetics method for the generation of 
RSVs with gene deletions, SH, NS1, NS2, and M2-2 were reported to be dispensable for viral 
replication in vitro and in vivo (6,8,11,52,88). Recombinant BRSV lacking the NS2 gene 
displayed an attenuated growth phenotype, indicating that NS2 is not essential for virus 
replication in cell culture but is required for full replication capacity (8). Similar results were 
obtained for an NS2 deletion mutant of HRSV which exhibited small plaque morphology and 
reduced replication in vitro (87). HRSV NS1 or NS2 deletion mutants are attenuated in 
chimpanzees and show restricted replication in the upper and lower respiratory tract (88,101). 
Moreover, studies from Jin et al. showed that recombinant HRSVs with deletions in the NS1, 
NS2, SH, and M2-2 genes, and various combinations thereof, are attenuated in vitro and in 
vivo (52).  
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BRSV NS proteins are IFN antagonists 
 
To examine more closely the function of the BRSV NS proteins, BRSV deletion mutants 
lacking the NS1 or NS2 gene, or both NS1 and NS2, were generated in our laboratory, and 
their behaviour in different cell lines was analysed. First, growth characteristics were analysed 
in BSR T7/5 cells which had been used for virus recovery. In comparison with the parental 
full- length virus, all three mutants were attenuated, suggesting a contribution of both NS 
proteins to virus replication (Fig. 6). Similar results were also obtained in Vero cells (data not 
shown). Then a cell line of bovine origin was used, MDBK, which had been shown to 
optimally support the growth of wt BRSV (8). Surprisingly, in this cell line growth of the NS 
deletion mutants was severely impeded whereas in other cells like BSR, the deletion mutants 
were only slightly attenuated (Fig. 6; 80).  
 
 
Fig. 6: NS deletion mutants are more attenuated in MDBK cells (B) than in BSR cells (A). Cells were 
infected at an MOI of 0.1 with BRSV wt, BRSV DNS1, BRSV DNS2, or BRSV DNS1/2, and virus titers were 
determined every 2 days. At day 8, infection of BSR cells (and MDBK cells in the case of BRSV wt) led to 
massive cell destruction. Bars show standard deviation (80). 
 
 
We therefore postulated the presence of MDBK cell factors, presumably produced upon virus 
infection, that are responsible for the selective impediment of the NS deletion mutants but not 
wt BRSV. To find out whether soluble molecules produced by MDBK cells are able to 
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restrain the growth of NS deletion mutants in Vero cells, MDBK and Vero cells were 
cocultured in devices in which the two cell cultures are separated by a virus-tight membrane 
filter allowing the passage of soluble factors. Supernatants from noninfected MDBK cells 
were not able to suppress the growth of the NS deletion mutants in Vero cells. However, 
cocultivation with MDBK cells infected with BRSV or BRSV deletion mutants resulted in a 
small but reproducible inhibition of the NS deletion mutants. In contrast, growth of wt BRSV 
was not affected (80). The antiviral effect caused by MDBK supernatants was abolished by 
incubation of Vero cells with an antibody blocking the binding of IFN to the IFN-a receptor  
(80). This identified IFN-a/b  as the critical host cell factors responsible for the observed 
attenuation in infected MDBK cells. While wt BRSV is able to counteract the IFN-induced 
antiviral state, neither NS deletion mutant can do so. Vero cells, in contrast to MDBK cells, 
lack IFN-a/b  genes (31,97), therefore virus infection does not result in the induction of an 
antiviral state, allowing the NS deletion mutants to grow.  
 
 
Fig. 7: All BRSV NS deletion mutants are IFN-a/b sensitive.  Vero cells infected at an MOI of 0.1 with BRSV 
wt, BRSV DNS1, BRSV DNS2, or BRSV DNS1/2 were incubated with the indicated amounts of recombinant 
IFN-a A/D (A) or IFN-b (B). Infectious virus titers were determined 3 days post infection. Bars show standard 
deviation (80). 
 
 
Finally, by stimulation of Vero cells with recombinant human IFN-a A/D or IFN-b , 
replication of the NS deletion mutants could be inhibited with all three mutants displaying a 
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highly similar, severe, and dose-dependent sensitivity towards the IFN-induced cellular 
response. In contrast, wt BRSV was significantly resistant to IFN treatment suggesting a 
function for the NS proteins in mediating virus escape from cellular antiviral mechanisms 
induced by IFN (Fig. 7; 80).  
 
 
 
 
4 AIM OF THIS STUDY 
 
Intriguingly, deletion of each NS gene or both NS genes from BRSV leads to deletion mutants 
that display approximately equal degrees of IFN sensitivity. This suggests that the presence of 
both NS proteins, NS1 and NS2, is required to protect BRSV from IFN-induced antiviral 
mechanisms and that each NS protein on its own does not possess IFN antagonist activity. I 
therefore wanted to develop an assay system to investigate the role(s) of NS1 and NS2 in 
mediating IFN resistance and to address a possible cooperative function of NS1 and NS2. 
Furthermore, I was interested to see whether IFN resistance can also be mediated by the NS 
proteins of other pneumoviruses such as HRSV and PVM, and whether cooperation of their 
NS proteins is necessary for the postulated IFN antagonist function. If so, this would suggest 
a common IFN resistance mechanism among Pneumovirinae members carrying NS genes. 
  
Pneumoviruses are known to display a very narrow host range that is only in part determined 
by their surface glycoproteins (9) requiring the presence of additional viral proteins that play a 
role in determining host range. To investigate whether the NS proteins have the potential to 
contribute to the host range restriction of BRSV, I decided to generate recombinant BRSVs 
that carry the NS genes of HRSV or PVM, instead of the homologous BRSV NS genes, in an 
identical virus background. The evaluation of these chimeric recombinants in cells of different 
hosts should allow to monitor possible host specific abilities of different NS proteins in 
antagonizing IFN-induced antiviral responses. 
 
Finally, I was also interested in elucidating the molecular mechanism(s) responsible for the 
observed IFN resistance of BRSV. 
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 MATERIALS AND METHODS 
 
1 MATERIALS 
  
1-1 Chemicals 
 
Chemicals were purchased from the following companies: Roth (acetone (tech.), DMSO, 
glycerol, glycine, HCl, Hepes, methanol, SDS, Tris, Tween 20, urea); Sigma (ATP, 
bromophenol blue, CDTA, digitonin, DOC, MgCO3xMg(OH)2, TEMED); Merck (CaCl2, 
EDTA, ethidium bromide, CH3COOK, KCl, MgSO4, MgCl2, CH3COONa, NaCl, NH4Cl, 
Orange G, paraformaldehyde, Phenol red, propidium iodide, Triton X-100); Riedel-de-Häen 
(ethanol, NaOH); Fluka (NP40, tricine); Boehringer Mannheim (DTT); ICN Biomedicals Inc. 
(APS); Pharmacia (Ficoll). 
 
1-2 Enzymes 
 
Restriction endonucleases, T4 DNA ligase (New England Biolabs),  klenow polymerase (MBI 
Fermentas),  pfu polymerase, AMV reverse transcriptase (Stratagene), RNase A, RNase I 
(Pharmacia),  shrimp alkaline phosphatase (Roche Biochemicals). 
 
1-3 Kits 
 
ECL detection kit « Renaissance »     NEN 
RNeasy kit         Qiagen 
QIAquick PCR purification/Gel extraction/Nucleotide removal  Qiagen 
Mammalian Transfection kit      Stratagene 
Nucleobond AX100, AX500      Macherey & Nagel 
 
1-4 Miscellaneous 
 
AcetylCoA        Sigma 
Acrylamide/Bisacrylamid solution (29:1)    Merck  
Agarose        Gibco BRL 
Ampicillin        Gibco BRL 
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Coomassie Protein Assay Reagent     Pierce 
DNA 1 kb ladder       Gibco BRL  
dNTPs        NEB 
Hyperfilm ECL       Amersham 
FuGENE        Roche  
Histogel        Linaris Biological Products 
IFN-a A/D        PBL  
Luciferin        Sigma 
Nitrocellulose membrane (0.5 mm)    Schleicher & Schuell 
Poly I/C        Sigma 
Prestained protein ladder      Gibco BRL 
RNasin        Pharmacia 
Skim milk powder       Merck 
Tryptone peptone        Difco 
Whatman paper       Roth 
Yeast extract       Difco 
 
1-5 Bacteria and plasmids 
 
E.coli XL1 (blue) or XL (gold; Stratagene) were used for preparation of plasmid DNA.  
 
All generated constructs as well as full- length cDNAs of rabies virus and BRSV are based on 
the Bluescript SKII- vector obtained from Pharmacia. 
 
pTIT-N, pTIT-P, pTIT-L plasmids containing RV N, P,or L gene 
under control of T7 promoter 
pTITB-N, pTITB-P, pTITB-M2, pTITB-L plasmids containing BRSV N, P, M2,or L 
gene under control of T7 promoter 
 
pSAD VB  plasmid containing full- length RV cDNA under T7-promoter 
control with additional stop-restart sequence between the G and L 
gene   
pSAD VB NS1ha   pSAD VB harboring BRSV NS1 gene between G and L gene 
pSAD VB NS2fl  pSAD VB harboring BRSV NS2 gene between G and L gene 
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pSAD VB hNS1  pSAD VB harboring HRSV NS1 gene between G and L gene 
pSAD VB hNS2  pSAD VB harboring HRSV NS2 gene between G and L gene 
pSAD VB mNS1ha  pSAD VB harboring PVM NS1 gene between G and L gene 
pSAD VB mNS2fl  pSAD VB harboring PVM NS2 gene between G and L gene 
pSAD VB NS2flNS1ha  pSAD VB harboring BRSV NS2-stop/restart-BRSV NS1 gene 
between G and L gene 
pNS1NS2 plasmid containing nt 1 to nt 957 of full length BRSV cDNA 
(encompassing the BRSV NS1 and NS2 genes) 
pNS1haNS2* pNS1NS2 harboring the BRSV NS1 gene with a C-terminal HA-
tag inserted at the HpaI restriction site (and containing an addition 
EcoRI restriction site; see Fig. 8) 
pNS1haNS2 pNS1NS2 harboring the BRSV NS1 gene with C-terminal HA-tag 
pNS1NS2fl pNS1NS2 harboring the BRSV NS2 gene with a C-terminal 
FLAG-tag 
phNS1NS2 pNS1NS2 harboring HRSV NS1 gene and BRSV NS2 gene 
pNS1hNS2 pNS1NS2 harboring BRSV NS1 gene and HRSV NS2 gene 
phNS1hNS2 pNS1NS2 harboring HRSV NS1 and HRSV NS2 genes 
pmNS1NS2 pNS1NS2 harboring C-terminally HA-tagged PVM NS1 gene and 
BRSV NS2 gene 
pNS1mNS2 pNS1NS2 harboring BRSV NS1 gene and C-terminally FLAG-
tagged PVM NS2 gene 
pmNS1mNS2 pNS1NS2 harboring C-terminally HA-tagged PVM NS1 gene and 
C-terminally FLAG-tagged PVM NS2 gene 
prBRSV plasmid containing full- length BRSV cDNA under T7-promoter 
control 
prBRSV NS1ha   prBRSV harboring C-terminal HA-tagged BRSV NS1 gene 
prBRSV NS2fl  prBRSV harboring C-terminal FLAG-tagged BRSV NS2 gene 
prBRSV hNS1NS2 prBRSV harboring HRSV NS1 gene instead of BRSV NS1 gene 
prBRSV NS1hNS2 prBRSV harboring HRSV NS2 gene instead of BRSV NS2 gene 
prBRSV hNS1hNS2 prBRSV harboring HRSV NS1 and NS2 genes instead of BRSV 
NS genes 
prBRSV mNS1NS2 prBRSV harboring PVM NS1 gene instead of BRSV NS1 gene 
prBRSV NS1mNS2 prBRSV harboring PVM NS2 gene instead of BRSV NS2 gene 
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prBRSV mNS1mNS2 prBRSV harboring PVM NS1 and NS2 genes instead of BRSV NS 
genes 
 
p125Luc luciferase gene under the control of the IFN-b  gene 
promoter/enhancer (kindly provided by T. Fujita, University of 
Kyoto, Japan) 
pEF-haIRF358-427 plasmid encoding IRF3 gene with aa 58-427 deleted (dominant 
negative form; kindly provided by T. Fujita, University of Kyoto, 
Japan) 
p55CIBLuc  luciferase gene under the control of the positive regulatory domain 
I (PRDI) of the IFN-b  gene promoter (kindly provided by T. 
Fujita, University of Kyoto, Japan) 
pNF-kBLuc  luciferase gene controlled by a synthetic promoter containing 5 
direct repeats of NF-kB binding sites (Stratagene) 
pAP-1Luc  luciferase gene controlley by a synthetic promoter containing 7 
direct repeats of AP-1 binding sites (Stratagene) 
 
1-6 Cells and viruses  
 
Cells  Origin  
BSR  Baby hamster kidney (BHK)  
BSR T7/5  BSR cells stably expressing T7 RNA polymerase 
Vero   African green monkey kidney 
MDBK  bovine kidney  
Klu   calf lung  
HEp-2  human nasopharyngeal epithelium  
293   human kidney (transformed by sheared human adenovirus type 5 DNA)  
NIH3T3   murine fibroblasts 
L929  murine lung epithelial cells 
 
Viruses  
SAD L16  recombinant Rabies Virus carrying nucleotide sequence of Street Alabama  
Dufferin B19, an attenuated Rabies Virus strain used for oral 
immunization with entire nucleotide sequence determined 
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SAD VB recombinant Rabies Virus carrying additional stop-start sequence between 
G and L gene 
rBRSV recombinant BRSV derived from strain A51908 (American Type Culture 
Collection) variant ATue51908 (GenBank accession no. AF092942) 
HRSV Long subgroup A strain, obtained from G. Herrler, Hannover 
 
Viruses generated during this thesis  
VB bNS1  SAD VB harboring BRSV NS1 gene between G and L gene 
VB bNS2  SAD VB harboring BRSV NS2 gene between G and L gene 
VB hNS1  SAD VB harboring HRSV NS1 gene between G and L gene 
VB hNS2  SAD VB harboring HRSV NS2 gene between G and L gene 
VB mNS1  SAD VB harboring PVM NS1 gene between G and L gene 
VB mNS2  SAD VB harboring PVM NS2 gene between G and L gene 
VB 2+1  SAD VB harboring BRSV NS2 and NS1 genes between G and L gene 
BRSV ha   rBRSV harboring HA-tag at C-terminus of NS1 gene 
BRSV fl  rBRSV harboring FLAG-tag at C-terminus of NS2 gene 
BRSV h1   rBRSV harboring HRSV NS1 gene and BRSV NS2 gene 
BRSV h2   rBRSV harboring BRSV NS1 gene and HRSV NS2 gene 
BRSV h1/2  rBRSV harboring HRSV NS1 and NS2 genes 
BRSV m1   rBRSV harboring PVM NS1 gene and BRSV NS2 gene 
BRSV m2   rBRSV harboring BRSV NS1 gene and PVM NS2 gene 
BRSV m1/2 rBRSV harboring PVM NS1 and NS2 genes 
 
1-7 Cell culture reagents 
 
Dulbecco’s modified eagle medium (DMEM)   Gibco BRL 
BHK-21 medium       Gibco BRL 
Phosphate buffered saline (PBS)     Gibco BRL   
Penicillin/Streptomycin 100x (P/S)    Sigma Cell Culture 
MEM amino acids (AA)      Gibco BRL 
Tryptose phosphate broth 50x (TP)    Gibco BRL 
Newborn calf serum (CS)      Gibco BRL 
Fetal calf serum (FCS)      Boehringer Mannheim  
Trypsin-EDTA 1x       Gibco BRL 
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Tissue culture flasks and plates     Nunc 
 
Cell line     medium 
BSR, BSR T7/5 cells   BHK-21 + 10% CS, 2% AA, 2% TP, 1% P/S  
VERO, MDBK and HEp-2 cells   DMEM + 5% FCS, 1% P/S  
A549, 293, Klu and NIH3T3 cells  DMEM + 10% FCS, 1% P/S 
 
1-8 Serological Reagents 
 
Primary antibodies: 
Rabbit a-STAT-2 (human, mouse), polyclonal  Santa Cruz Biotechnology, Inc. 
Rabbit a-ISGF 3g (p48; IRF-9), polyclonal  Santa Cruz Biotechnology, Inc. 
Rabbit a-PCNA, monoclonal    Santa Cruz Biotechnology, Inc. 
Rabbit a-IRF-3, polyclonal    Santa Cruz Biotechnology, Inc. 
Rabbit a-HA (Y-11), polyclonal    Santa Cruz Biotechnology, Inc. 
Mouse a-FLAG (M2), monoclonal   Sigma  
Rabbit a-HRSV NS1 (a-NS1), polyclonal  generous gift from J.A. Melero 
Rabbit a-HRSV NS1 (a-IC/C), polyclonal  generous gift from J.A. Melero 
Mouse a-HRSV nucleoprotein (79N), monoclonal generous gift from J.A. Melero 
Mouse a- RSV F protein, monoclonal   Serotec 
Goat a-RSV serum, polyclonal    Biogenesis 
Mouse a-p68 (C-10), monoclonal    H. Stahl, Saarbrücken 
Rabbit a-RV N and P protein (S50), polyclonal  BFAV  
 
All secondary antibodies (FITC-, Cy3-, and peroxidase-conjugated anti-mouse or anti-rabbit 
IgGs) were obtained from Dianova. A FITC-conjugate recognizing RV N protein 
(Centocorâ) was obtained from Centocor. Normal goat serum was purchased from Dianova.  
 
1-9 Frequently used buffers 
 
Anode buffer  2 M Tris HCl; pH [8.9] 
Cathode buffer  1 M Tris, 1 M Tricin, 1% SDS 
Cell lysis buffer 10 mM Tris HCl pH [7.5], 100 mM NaCl, 10 mM EDTA, 0.5% 
Triton X-100, 0.5% DOC 
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DNA loading buffer (1x)  15% Ficoll 400, 5x TAE, 0,125% Orange G 
Flexi I buffer 100 mM Tris-HCl pH [7.5], 10 mM EDTA pH [8.0], 400 mg/ml 
RNase I 
Flexi II buffer  200 mM NaOH, 1% SDS 
Flexi III buffer  300 mM KCH3COO; pH [5.75] 
Gel buffer 3 M Tris HCl pH [8.45], 0.3%SDS,  
LB medium 0.5% NaCl, 0.5% yeast extract, 1% tryptone peptone, 1 mM 
MgSO4 
Luciferase lysis buffer 20 mM Tris HCl pH [7.8], 2 mM DTT, 2 mM CDTA, 10% 
glycerol, 1% Triton X-100 
Luciferase substrate buffer 20 mM tricine, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 
1.07 mM MgCO3 x Mg(OH)2 x 5 H2O 
Lysis buffer 6.25 mM Tris HCl pH [6.8], 2% SDS, 10% glycerol, 6 M urea, 5% 
methanol, 0.01% bromophenol blue, 0.01% phenol red 
NP40 buffer 10 mM Hepes pH [7.9], 10 mM NaCl, 3 mM MgCl2, 0.5% NP40 
RT buffer (10x)   0.5 M Tris pH [8.3], 0.3 M KCl, 0.1 M MgCl2, 0.05 M DTT 
PBS 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4; 
pH [7.5] 
SEB (3x)  83.3 mM Tris HCl; pH [6.8], 33.3% glycerol, 6.7% SDS, 16.7% ß-
mercaptoethanol, bromophenol blue 
TAE (1x)   40 mM Tris, 5 mM CH3COONa x 3 H2O, 1 mM EDTA 
Transfer buffer 48 mM Tris pH [8.6], 39 mM glycine, 18% methanol, 0.005% 
SDS 
Walter solution  50 mM NH4Cl, 20 mM glycine 
 
1-10 Oligonucleotides 
 
Oligonucleotides were obtained either from MWG Biotechnology Inc. or Metabion. Major 
restriction recognition sites are underlined. 
 
NS1HA-EcoRI 3’ 5’-gca ata gaa ttc cta agc gta atc tgg gac atc ata agg ata att cag acc 
aag aag agt-3’ 
NS2FL-EcoRI 3’ 5’-gca ata gaa ttc cta ttt atc gtc atc atc ttt ata atc tgg att taa atc ata 
ctt ata-3’ 
NS1NcoI-5’  5’-cga ata cca tgg gca gtg aaa cat tga g-3’ 
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NS2BspHI-5’  5’-gca ata tca tga gca ccc caa atc ccg aa-3’ 
hNS1-NcoI 5’  5’-att gac cat ggg cag caa ttc att-3’ 
hNS2-NcoI 5’  5’-att gac cat gga cac aac cca ca-3’ 
hNS1-NotI 5’ 5’-tat gaa gcg gcc gcc ccc tct ctt ctt tct aca gaa aat ggg cag caa ttc 
att gag-3’ 
hNS1-EcoRI 3’  5’-att gag aat tct tat gga tta aga tca aa-3’ 
hNS2-AseI 5’ 5’-ata ctt att aat tgg ggc aaa taa atc agt tcc cca acc agc cat gga cac 
aac cca caa tg-3’ 
hNS2-KpnI 3’ 5’-ata aat ggt acc aaa aga taa cac tgt gtg aat taa att ttg aaa agt gct 
tat gga ttg aga tca tac ttg-3’ 
mNS1haEcoRI/V-3’  5’-aat gat atc gaa ttc tta agc gta atc tgg tac atc ata agg ata acc act 
gat cag ctc tac-3’ 
mNS1NotIEcoRV-5’ 5’-aat gat atc gcg gcc gcc ccc tct ctt ctt tct aca gaa atg ggc tgt aat 
gtg atg atg-3’ 
mNS2flEcoRI/V-3’ 5’-aat gat atc gaa ttc tca ttt atc gtc atc atc ttt ata gtc atc atc atc ctc 
atc-3’ 
mNS2AseIEcoRV-5’ 5’-aat gat atc att aat tgg ggc aaa taa atc agt tcc cca acc agc cat gtc 
cac agc tat gaa caa g-3’ 
mNS2Acc65I 3’ 5’-ata aat ggt acc aaa aga taa cac tgt gtg aat taa att ttg aaa agt gct 
cat tta tcg tca tca tct tta tag-3’ 
bNS2BamHI 5’  5’-aag cgg atc ccc aac cag cca tga gca cc-3’ 
bNS1-NotIEcoRV 5’ 5’-aat gat atc gcg gcc gcc ccc tct ctt ctt tct aca gaa atg ggc agt gaa 
aca ttg agt g-3’ 
 
 
2 METHODS 
 
2-1 General cloning procedures 
 
Restriction endonuclease digests were done according to the supplier’s manual using 10 
units/mg plasmid. Restriction fragments were separated on 1% agarose gels using 1x TAE (40 
mM Tris, 5 mM CH3COONa x 3 H2O, 1 mM EDTA) containing 0,1 mg/ml ethidium bromide 
as electrophoresis buffer. The samples were supplemented with 1x DNA loading buffer (15% 
Ficoll 400, 5x TAE, 0,125% Orange G) prior to loading. To recover a DNA fragment, the 
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respective band was excised from the gel under UV-light and purified using the QIAquick gel 
extraction kit (Qiagen) following the supplier’s manual. 
 Standard procedures were applied for DNA ligation and transformation of DNA into 
competent E.coli XL1 or XL10 prepared by the calcium chloride method. 
 The following protocol was used to screen for positive clones (miniprep). 1.5 ml of an 
overnight culture were centrifuged for 5 min at 7,000 rpm (Eppendorf table centrifuge). The 
supernatant was discarded and the pellet resuspended in 0.2 ml Flexi I buffer (100 mM Tris-
HCl pH [7.5], 10 mM EDTA pH [8.0], 400 mg/ml RNase I). 0.2 ml of Flexi II buffer (200 mM 
NaOH, 1% SDS) were then added to lyse the cells (5 min at room temperature), followed by 
the addition of 0.2 ml of Flexi III buffer (300 mM KCH3COO; pH [5.75]) to precipitate 
cellular debris and chromosomal DNA during a 10 min incubation on ice. After centrifugation 
for 10 min at 14,000 rpm the supernatant was carefully transferred to a fresh tube and the 
plasmid DNA was precipitated with 1 ml ethanol for at least 30 min on ice. The plasmid DNA 
was then pelleted by centrifugation and resuspended in dH2O followed by restriction enzyme 
analysis to establish the correct clone.  
For the preparation of larger amounts of plasmid DNA, overnight cultures grown in 25 
ml or 100 ml LB medium (0.5% NaCl, 0.5% yeast extract, 1% tryptone peptone, 1 mM 
MgSO4) supplemented with ampicillin (100 mg/ml) were used and plasmid DNA purified 
using the Nucleobond plasmid purification kits. 
 
2-2 PCR and reverse transcriptase reaction 
 
In a standard PCR reaction, 100 ng of template DNA were mixed with 250-500 ng of each of 
the respective oligonucleotides used as primer, 0.8 ml dNTPs (25 mM of each dATP, dCTP, 
dGTP and dTTP), 10 ml DMSO, 10 ml 10x buffer (supplied by the manufacturer), and 0.5 ml 
pfu polymerase in a total volume of 100 ml. The reaction was then carried out in a 
thermocycler (T3 Thermocycler, Biometra), starting with a 10 min step at 94°C, followed by 
35 cycles of the following protocol: a denaturation step for 1 min at 94°C, an annealing step 
of 1-2 min at 42-58°C (temperature depending on the length and GC-content of the 
oligonucleotides used in the reaction), and a polymerization step of various length at 72°C 
(depending on the size of the DNA fragment to be amplified). The resulting DNA fragment 
was purified using the Qiagen PCR purification kit.  
For reverse transcriptase (RT) reactions, RNA was isolated from infected or mock-
infected cells seeded into 6-well plates using the Qiagen RNeasy kit. 1 mg of RNA was then 
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mixed with 100 ng of the desired oligonucleotide and 0.3 ml RNasin in a total volume of 23 
ml, incubated for 4 min at 65°C followed by 10 min at 37°C. Then 3 ml dNTPs (25 mM each), 
3 ml 10x RT buffer (0.5 M Tris pH [8.3], 0.3 M KCl, 0.1 M MgCl2, 0.05 M DTT) and 1 ml 
AMV reverse transcriptase were added, and the reaction was incubated for 1 hr at 43°C. 3 ml 
of the sample were then used as template in a standard PCR reaction.  
 
2-3 Generation of recombinant RVs expressing pneumovirus NS proteins 
 
Recombinant Rabies Viruses carrying the NS1 or NS2 genes from different pneumoviruses 
were constructed on the basis of a full- length RV cDNA (SAD L16) containing an extra 
transcriptional stop-restart sequence in the 3’ noncoding sequence of the G gene (SAD VB) 
(66). 
For the BRSV NS genes, cDNAs encoding C-terminally tagged BRSV NS1 or NS2 
proteins were constructed. An additional 27 nt corresponding to an internal region of the 
influenza virus hemagglutinin (HA) protein were inserted right before the NS1 stop codon by 
PCR using a reverse primer NS1HA-EcoRI 3’ (5’-gca ata gaa ttc cta agc gta atc tgg gac atc 
ata agg ata att cag acc aag aag agt-3’) containing an EcoRI recognition sequence (underlined) 
and NS1NcoI-5’ (5’-cga ata cca tgg gca gtg aaa cat tga g-3’). For NS2, 24 nt encoding the 
synthetic FLAG peptide were inserted C-terminally with reverse primer NS2FL-EcoRI 3’ (5’-
gca ata gaa ttc cta ttt atc gtc atc atc ttt ata atc tgg att taa atc ata ctt ata-3’) and NS2BspHI-5’ 
(5’-gca ata tca tga gca ccc caa atc ccg aa-3’). The NS1ha PCR fragment was digested with 
NotI and EcoRI. After the generation of blunt ends with klenow polymerase, the resulting 475 
nt fragment was inserted into the unique SmaI site in pSAD VB immediately downstream of 
the extra transcription start signal, leading to pSAD VB NS1ha (VB bNS1). A 470 nt 
fragment containing NS2fl was cloned accordingly after digestion with AseI and EcoRI and 
filling in with klenow polymerase, resulting in pSAD VB NS2fl (VB bNS2). 
  
For construction of rRVs carrying the HRSV NS1 and NS2 genes, cDNAs of both genes were 
obtained by RT-PCR using total RNA isolated from HRSV (Long) infected Vero cells as 
template with the following primers for first-strand synthesis: hNS1-NcoI 5’ (5’-att gac cat 
ggg cag caa ttc att-3’) for HRSV NS1 and hNS2-NcoI 5’ (5’-att gac cat gga cac aac cca ca-3’) 
for HRSV NS2. A PCR fragment encompassing the entire HRSV NS1 gene was then 
generated with primers hNS1-NotI 5’ (5’-tat gaa gcg gcc gcc ccc tct ctt ctt tct aca gaa aat ggg 
cag caa ttc att gag-3’) and hNS1-EcoRI 3’ (5’-att gag aat tct tat gga tta aga tca aa-3’). For the 
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HRSV NS2 fragment, primers hNS2-AseI 5’ (5’-ata ctt att aat tgg ggc aaa taa atc agt tcc cca 
acc agc cat gga cac aac cca caa tg-3’) and hNS2-KpnI 3’ (5’-ata aat ggt acc aaa aga taa cac tgt 
gtg aat taa att ttg aaa agt gct tat gga ttg aga tca tac ttg-3’) were used. The PCR fragments were 
digested with NotI and EcoRI in the case of NS1 or digested with AseI and Acc65I in the case 
of NS2, followed by generation of blunt ends with klenow polymerase. The resulting 
fragments were then inserted into the SmaI site of pSAD VB leading to pSAD VB hNS1 (VB 
hNS1) and pSAD VB hNS2 (VB hNS2), respectively. 
 
For the generation of rRVs carrying the PVM NS1 or NS2 gene, cDNAs of PVM NS1 and 
NS2 were kindly provided by A. Easton (Warwick, UK). For the NS1 gene, an HA-tag was 
inserted right before the NS1 stop codon by PCR using a reverse primer mNS1haEcoRI/V-3’ 
(5’-aat gat atc gaa ttc tta agc gta atc tgg tac atc ata agg ata acc act gat cag ctc tac-3’) and 
mNS1NotIEcoRV-5’ (5’-aat gat atc gcg gcc gcc ccc tct ctt ctt tct aca gaa atg ggc tgt aat gtg 
atg atg-3’). In the case of NS2, a FLAG-tag was inserted C-terminally using reverse primer 
mNS2flEcoRI/V-3’ (5’-aat gat atc gaa ttc tca ttt atc gtc atc atc ttt ata gtc atc atc atc ctc atc-
3’) and mNS2AseIEcoRV-5’ (5’-aat gat atc att aat tgg ggc aaa taa atc agt tcc cca acc agc cat 
gtc cac agc tat gaa caa g-3’). Both PCR fragments were digested with EcoRV and inserted 
into the SmaI site of pSAD VB resulting in pSAD VB mNS1ha (VB mNS1) and pSAD VB 
mNS2fl (VB mNS2), respectively. 
 
A recombinant RV carrying both NS genes of BRSV was constructed using a plasmid 
containing an extra transcription stop-restart sequence (SK9; (66)). A PCR fragment 
harboring the NS2fl gene was generated using primers bNS2BamHI 5’ (5’-aag cgg atc ccc aac 
cag cca tga gca cc-3’) and NS2FL-EcoRI3’, digested with BamHI and EcoRI and inserted into 
SK9 previously digested with BamHI and EcoRI right before the stop-start sequence, giving 
rise to SK9 NS2fl. The NS1ha fragment was generated by PCR using primers bNS1-
NotIEcoRV 5’ (5’-aat gat atc gcg gcc gcc ccc tct ctt ctt tct aca gaa atg ggc agt gaa aca ttg agt 
g-3’) and NS1HA-EcoRI3’, digested with NotI and EcoRI followed by klenow treatment, and 
inserted into SK9 NS2fl digested with BglII and treated with klenow, resulting in SK9 
NS2flNS1ha. This plasmid was then digested with NotI and Acc65I followed by the 
generation of blunt ends with klenow polymerase, resulting in a large fragment encompassing 
NS2-stop/restart-NS1 which was then inserted into the unique SmaI site of pSAD VB 
resulting in pSAD VB NS2flNS1ha (VB 2+1). 
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2-4 Generation of recombinant BRSVs expressing NS1ha or NS2fl 
 
For the generation of rBRSV expressing NS1ha or NS2fl, respective cDNAs were used to 
substitute corresponding sequences of a plasmid (pNS1NS2cass) containing nt 1 to 957 of the 
full length BRSV cDNA (8).  
 
 
 
Fig. 8: Cloning diagram for the construction of pNS1haNS2 and pNS1NS2fl.  Open reading frames are 
shown as white bars. Important restriction sites are indicated. 
 
For substitution of the NS1 gene, pNS1NS2cass was digested with HpaI located at nt 311 of 
the NS1 cDNA. The C-terminal part of the NS1ha gene was cut out of a pTIT-expression 
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plasmid (pTIT-NS1ha) with HpaI and BamHI, followed by the conversion of overhanging 
DNA ends generated by the restriction digest into blunt ends using klenow polymerase (in the 
following referred to as “klenow treatment”), and was then inserted into pNS1NS2cass 
resulting in pNS1haNS2*.  As a next step, to remove the remaining original NS1 cDNA (nt 
313-443), pNS1haNS2* was digested with EcoRI (restriction site was inserted with the 
NS1ha cDNA), klenow-treated, and digested with KpnI. Then pNS1NS2cass was digested 
with EarI, followed by klenow treatment, and subsequently digested with KpnI. The resulting 
fragment encompassing the intergenic region and the entire coding region of NS2 was then 
inserted into pNS1haNS2* giving rise to pNS1haNS2 (Fig. 8). This plasmid was digested 
with NotI and Acc65I and the resulting fragment inserted into full- length BRSV cDNA 
previously digested with NotI and Acc65I, giving rise to pBRSV NS1ha (BRSV ha). For 
NS2fl, pNS1NS2cass was digested with ApoI, followed by klenow treatment and a partiell 
digest with BsiHKAI. A fragment encompassing almost the entire NS2fl coding region was 
obtained by digesting pSKNS2fl with EcoRV and BsiHKAI. This fragment was inserted into 
pNS1NS2cass giving rise to pNS1NS2fl (see also Fig. 8). This plasmid was also digested with 
NotI and Acc65I, and the resulting fragment was inserted into full- length BRSV cDNA 
resulting in pBRSV NS2fl (BRSV fl). 
 
2-5 Generation of rBRSVs expressing HRSV or PVM NS proteins 
 
rBRSVs carrying either HRSV or PVM NS1 were generated using pNS1haNS2* that contains 
an additional EcoRI restriction site at nt 311 (see 2-4). Restriction digest with NotI and EcoRI 
removes the entire coding region of BRSV NS1ha. PCR fragments containing either the 
HRSV or the PVM NS1 gene were generated using primers hNS1-NotI 5’ and hNS1-EcoRI 3’ 
in case of HRSV NS1, and primers mNS1NotI/EcoRV-5’ and mNS1haEcoRI/V-3’ for PVM 
NS1. Both PCR fragments were digested with NotI and EcoRI and inserted into pNS1haNS2 
resulting in phNS1NS2 or pmNS1NS2. These plasmids were then digested with NotI and 
Acc65I, and the obtained fragments (1094 nt for hNS1NS2, 1043 nt for mNS1NS2) were 
inserted into full- length BRSV cDNA, also previously digested with NotI and Acc65I, giving 
rise to pBRSV hNS1NS2 (BRSV h1 ) and pBRSV mNS1NS2 (BRSV m1 ).  
 For generation of rBRSVs carrying either HRSV or PVM NS2, pNS1NS2cass was first 
digested with Acc65I, followed by a partial digest with AseI. PCR fragments harboring the 
coding region of HRSV or PVM NS2 were generated with primers hNS2-AseI 5’ and hNS2-
Acc65I 3’ for HRSV NS2, and primers mNS2AseIEcoRV-5’ and mNS2Acc65I 3’ (5’-ata aat 
ggt acc aaa aga taa cac tgt gtg aat taa att ttg aaa agt gct cat tta tcg tca tca tct tta tag-3’) in the 
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case of PVM NS2. Both PCR fragments were digested with AseI and Acc65I and inserted into 
pNS1NS2cass (949 nt for NS1hNS2, 1069 nt for NS1mNS2), resulting in pNS1hNS2 or 
pNS1mNS2. These plasmids were then digested with NotI and Acc65I, and each fragment 
was inserted into full- length BRSV cDNA resulting in pBRSV NS1hNS2 (BRSV h2 ) and 
pBRSV NS1mNS2 (BRSV m2), respectively.  
 rBRSVs expressing both NS genes from either HRSV or PVM were generated according 
to the protocol described for the generation of pNS1hNS2 or pNS1mNS2. However, instead 
of pNS1haNS2*, phNS1NS2 or pmNS1NS2 were used giving rise to phNS1hNS2 and 
pmNS1mNS2, respectively. These plasmids were then digested with NotI and Acc65I and the 
resulting fragments (1094 nt for hNS1hNS2, 1163 nt for mNS1mNS2) inserted into full-
length BRSV cDNA giving rise to pBRSV hNS1hNS2 (BRSV h1/2) or pBRSV mNS1mNS2 
(BRSV m1/2). 
 
2-6 Recovery of recombinant rBRSV and rRV 
 
Recombinant BRSVs were rescued as described previously (8) using plasmids containing the 
respective virus cDNA or coding regions for BRSV N, P, L and M2 proteins under the control 
of the T7-promoter. BSR T7/5 cells stably expressing T7 polymerase were grown overnight to 
80% confluency in 35 mm-diameter dishes in BHK-21 medium supplemented with 10% FCS. 
One hour before transfection, cells were washed once with DMEM without FCS, then 1 ml 
DMEM was added to each dish. One hour later, cells were transfected with a plasmid mixture 
containing 10 mg of full- length plasmid (pBRSV NS1ha, pBRSV NS2fl, pBRSV hNS1NS2, 
pBRSV NS1hNS2, pBRSV hNS1hNS2, pBRSV mNS1NS2, pBRSV NS1mNS2, or pBRSV 
mNS1mNS2), 4 mg of pTITB-N and pTITB-P, and 2 mg of pTITB-L and pTITB-M2 using the 
CaPO4-method (Mammalian transfection kit, Stratagene; plasmids see sections 1-5; 2-4; 2-5). 
The transfection medium was removed 4 hours post transfection, and cells were maintained in 
BHK-21 medium containing 10% FCS. Three days post transfection, cells were split at a ratio 
of 1:3 and maintained in BHK-21 medium supplemented with 2.5% FCS. Cells were then 
split every 4-5 days until a cytopathic effect (CPE; for RSV the formation of syncytia) was 
observed.  
Recombinant RVs were rescued as described previously (34). BSR T7/5 cells were 
grown as described above. Plasmids encoding RV proteins N (pTIT-N, 5 mg), P and L (pTIT-
P and pTIT-L, 2.5 mg each) were cotransfected with the respective virus cDNA (pSAD VB 
NS1ha, pSAD VB NS2fl, pSAD VB hNS1, pSAD VB hNS2, pSAD VB mNS1ha, pSAD VB 
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mNS2fl, or pSAD VB NS2flNS1ha, 10 mg each) using the CaPO4-method (Mammalian 
transfection kit, Stratagene). The transfection medium was removed 3.5 hours post 
transfection, and cells were maintained in BHK-21 medium containing 10% CS. Cell culture 
supernatants were harvested 3 and 6 days post transfection and transferred onto fresh BSR 
cells. Infectious rRVs were detected by immunostaining of aceton-fixed (80% aceton) cells 
with a fluorescein isothiocyanate conjugate (Centocorâ) recognizing the RV N protein. 
 
2-7 Production of virus stocks 
 
For preparation of RSV stocks, 80% confluent Vero cells grown in medium 80 cm2 tissue 
culture flasks were infected at a multiplicity of infection (MOI) of 0.01 to 0.1 in serum free 
DMEM. After an incubation time of 1.5 hours, the inoculum was removed, and cells were 
incubated in DMEM supplemented with 2.5% FCS until an extensive CPE was observed. 
Virus was released by one cycle of freezing and thawing, followed by centrifugation at 3,500 
rpm in a centrifuge (Heraeus Varifuge 3.0R) for 5 min to remove cell debris. The supernatant 
was then aliquoted (1 ml aliquots) and stored at –70°C. Virus titers were determined on Vero 
cells as follows. Vero cells from a confluent 25 cm2 flask were trypsinized and resuspended in 
30 ml DMEM containing 5% FCS, and distributed into 96-well microtiter plates (100 ml per 
well). Virus stocks were stepwise 10-fold diluted in DMEM and 100 ml of each dilution was 
pipetted into the wells. Three days post infection, cells were fixed with 80% acetone for 30 
min at 4°C, dried, and afterwards stained with an antibody recognizing the RSV fusion 
protein (Serotec, diluted 1:70 to 1:100 in PBS) for 45 min at 37°C. After washing the cells 
twice with PBS, a secondary, FITC-conjugated anti-mouse antibody (diluted 1:100 in PBS) 
was applied for 45 min at 37°C. The cells were then washed once with PBS and once with 
dH2O, and virus titers were determined by counting of infected cell foci using a fluorescent 
microscope (Zeiss Axiovert 35). 
 
For production of Rabies virus stocks, 80% confluent BSR cells were infected at an MOI of 
0.1 to 1 for 1 hour. Afterwards, the cells were incubated in BHK-21 medium supplemented 
with 10% CS, and  supernatants were harvested 3 days post infection. If possible, supernatants 
were harvested a second time 6 days post infection. The supernatants were centrifuged for 5 
min at 3,500 rpm (Haereus Varifuge 3.0R) to remove cell debris, aliquoted (0.4 ml aliquots), 
and aliquots were stored at –70°C. To determine virus titers, confluent BSR cells from a 25 
cm2 flask were trypsinized and resuspended in 20-25 ml BHK-21 medium containing 10% CS 
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and distributed into 96-well microtiter plates (100 ml per well). Virus stocks were diluted 
stepwise in BHK-21 medium, and 100 ml of each dilution was pipetted into the wells. Two 
days post infection, cells were fixed with 80% acetone for 30 min at 4°C, dried, and then 
incubated with Centocor (diluted 1:200 in PBS) for at least 45 min at 37°C. Cells were 
washed twice with dH2O, and virus titers were determined by counting of infected cells using 
a fluorescent microscope (Zeiss, Axiovert 35). 
 
2-8 Infection experiments and treatment with IFN 
 
To determine the growth characteristics of various recombinant BRSVs, different cell lines 
were infected in suspension at an MOI of 0.1 for 1 hour in serum free DMEM using 15 ml 
falcon tubes for incubation. To keep cells in suspension, tubes were slighty shaken every 15 
min. Afterwards, cells were incubated in 12-well plates in 1 ml DMEM containing 2.5% FCS. 
Slightly different numbers of cells were used for each cell line in infection experiments 
according to cell size (Vero 4x105 cells/well, MDBK 3.5x105 cells/well, HEp-2 and Klu 
2.5x105 cells/well). Virus was harvested at the indicated time points by two cycles of freezing 
and thawing, and virus titers were determined as described above (2-7).  
 To measure the effect of IFN-a/b  on viral replication, cells were infected at an MOI of 
0.1 as described above, and recombinant IFN-a A/D (PBL Biomedical Laboratories) was 
added to concentrations of up to 10,000 IU/ml cell culture medium directly after seeding 
using a dilution of 100 IU/ml IFN-a in PBS as working concentration. Virus titers were 
determined 2 or 3 days post infection depending on the extend of the observed CPE. 
 
Infection of MDBK (Vero) cells with recombinant rRVs expressing pneumovirus NS proteins 
were done in suspension at an MOI of 5 (2) for 1 hour in serum free DMEM.  For 
coinfections, an MOI of 2.5 (1) was used for each recombinant virus. Recombinant IFN-a 
A/D was added to concentrations of up to 500 IU/ml immediately after seeding of cells 
(MDBK and Vero 4x105 cells/well) into 12-well plates. Cell supernatants were harvested 2 
days post infection, centrifuged to remove cell debris, and virus titers were determined as 
described above. In addition, cells were harvested with 200 ml lysis buffer, and in the case of 
infection with VB bNS1 and VB bNS2, extracts were subjected to SDS-PAGE followed by 
detection of RV N and P proteins with antibody S50 (1:20,000 in PBS-T; see also 2-9). 
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2-9 Western blot analysis of pneumovirus NS proteins 
 
To monitor the expression of pneumovirus NS proteins from recombinant BRSVs, Vero cells 
were mock-infected or infected with the respective BRSV at an MOI of 0.1 as described 
above and seeded into 6-well plates in 2 ml DMEM supplemented with 2.5% FCS. Three 
days post infection, cells were lysed with 500 ml lysis buffer (6.25 mM Tris HCl pH [6.8], 2% 
sodium dodecyl sulfate [SDS], 10% glycerol, 6 M urea, 5% methanol, 0.01% bromophenol 
blue, 0.01% phenol red). In the case of recombinant RVs expressing pneumovirus NS 
proteins, BSR cells were infected with the respective recombinant viruses at an MOI of 1 as 
described above and seeded into 6-well plates. Three days post infection, cells were lysed 
with 500 ml lysis buffer. Cell extracts were incubated at 95°C for 5 min, and equivalent 
amounts (50 ml/well) were loaded onto a 12% gel for sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE; Penguinä  Model P9DS [OWL scientific], 16x14 cm, 40 V 
12-14 h run). The proteins were transferred to a nitrocellulose membrane in a semidry transfer 
apparatus (ThePantherä  Model HEP-1 [OWL scientific]) using the following transfer buffer: 
48 mM Tris pH [8.6], 39 mM glycine, 18% methanol, 0.005% SDS. After the transfer, the 
membrane was incubated in blocking solution (0.05% Tween-20 in phosphate-buffered saline 
[PBS-T] supplemented with 5% skim milk powder) for 45 min at room temperature. After 
two consecutive washes with PBS-T for 15 min each, the membrane was incubated overnight 
at 4°C or 4 hours at room temperature in primary antibody solution (HRSV NS proteins were 
detected using a-NS1 and a-IC/C antibodies [1:5,000-1:7,000 in PBS-T; both kindly 
provided by J.A. Melero, Madrid, Spain], BRSV and PVM NS1ha were detected with Y-11 
antibody [1:1,000 in PBS-T], BRSV and PVM NS2fl with M2 antibody [1:20,000 in PBS-T]) 
followed by two consecutive washes with PBS-T for 15 min each. Afterwards, the membrane 
was incubated with secondary antibody solution for 2 hours at room temperature (peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG; 1:10,000 in PBS-T). The membrane was then 
washed twice with PBS-T for 15 min each, followed by incubation of the membrane in ECL 
solution (1.5 ml solution #1, 1.5 ml solution #2, 7 ml PBS-T) for 1 min. Exposure times to 
Hyperfilm ECL (Amersham) varied depending on signal strength from 5 sec up to several 
minutes. 
10% gel  12% gel (sufficient for one 14x16 cm gel) 
polyacrylamide     9.0 ml    10.8 ml 
gel buffer    12.0 ml    12.0 ml 
dH2O     12.9 ml    11.1 ml 
glycerol      2.0 ml      2.0 ml 
TEMED  0.017 ml  0.017 ml 
APS   0.175 ml  0.175 ml 
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Gel buffer (3 M Tris HCl, pH [8.45]; 0.3% SDS)  
Anode buffer (2 M Tris HCl, pH [8.9]) 
Cathode buffer (1 M Tris, 1 M Tricin, 1% SDS) 
 
2-10 Immunofluorescent staining 
 
For immunostaining, cells were seeded out onto coverslips placed into 6-well plates directly 
after infection (BRSVs: MOI 0.1, RVs: MOI 0.1-1.0). At most, 4x105 cells were used per 
well. At the indicated time points, cells were fixed in PBS containing 3% paraformaldehyde 
for 20 min at room temperature, follwed by incubation in Walter solution (50 mM NH4Cl, 20 
mM glycine) for 10 min at room temperature. After two washes with PBS, cells were 
permeabilized with 0.5% Triton X-100 in PBS for 10 min at room temperature. Next, cells 
were washed twice in PBS, followed by a 15 min incubation step in blocking solution (PBS 
containing 10% goat normal serum). The cells were then incubated in 100 ml primary 
antibody solution for 45 min at room temperature [1.5% goat normal serum in PBS; detection 
of BRSV and PVM NS1ha with antibody Y-11 (1:100); BRSV and PVM NS2fl with antibody 
M2 (1:2,000); STAT2 with a-STAT2 antibody (1:100); BRSV N protein with antibody 79N 
(1:40; kindly provided by J.A. Melero, Madrid, Spain)]. After two washes with PBS, cells 
were incubated in secondary antibody solution (1.5% goat normal serum in PBS; FITC- or 
Cy3-conjugated anti-rabbit or anti-mouse IgG 1:200) for 45 min at room temperature. Cells 
were washed twice with PBS and once with dH2O and then embedded in embedding medium 
(50% glycerol or Histogel). Cells were analysed using a laser scan microscope (Leica TCS 
NT). 
 For staining of cell nuclei with propidium iodide, cells were incubated for 45 min with 
100 ml of staining solution containing 1 ml propidium iodide (10 mg/ml), 1 ml EDTA 0.5M 
and 1 ml RNase A (20 mg/ml) in PBS. 
 Digitonin treatment of cells was performed as follows. Cells were treated with digitonin 
(40 mg/ml in PBS) for 3 min on ice, then washed once with cold PBS. Next, cells were 
incubated with 0.025% Triton X-100 in PBS for 5 min on ice before fixation in 3% 
paraformaldehyde. Permeabilization using 0.2% Triton X-100 in PBS and staining of cells 
were performed as described above. For the GFP control, Vero cells were transfected with 2 
mg pEGFP-N3 (Clontech) using the FuGENE 6 transfection reagent (Roche). An antibody 
recognizing the nuclear RNA helicase p68, C-10, was used 1:2000 in antibody solution (1.5% 
goat normal serum in PBS). 
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2-11 Monitoring ISG expression 
 
HEp-2, L929 (2.5x105/well), MDBK or NIH3T3 (3x105/well) cells were mock- infected or 
infected with the indicated rBRSVs at an MOI of 0.2 as described above (2-8) and seeded into 
12-well plates. When indicated, mock- infected MDBK and HEp-2 cells were treated with 
2,000 IU IFN-a A/D per ml medium directly after seeding. Cells were lysed in 150-200 ml 
cell lysis buffer (10 mM Tris HCl pH [7.5], 100 mM NaCl, 10 mM EDTA, 0.5% Triton X-
100, 0.5% DOC) at indicated time points. Equal amounts of cell extracts (30-50 ml per lane; 
determined with Coomassie Protein Assay Reagent, Pierce) were mixed with 25 ml 3x SEB 
(83.3 mM Tris HCl pH [6.8], 33.3% glycerol, 6.7% SDS, 16.7% ß-mercaptoethanol, 
bromophenol blue) and loaded onto a 10% SDS-polyacrylamide gel. Proteins were transferred 
and the membrane was probed with antibodies recognizing STAT-2, PKR, p48 and PCNA 
(1:1000 in PBS-T; see also 2-9). 
 
2-12 Detection of IFN in supernatants 
 
Biological active IFN was detected in cell culture supernatants making use of the sensitivity 
of RV to IFN in MDBK cells. MDBK cells (4x105/well) were infected in suspension with 
SAD VB at an MOI of 5 for 1 hour. Then cells were seeded into 12-well plates in DMEM 
supplemented with 2.5% FCS using a total volume of 500 ml per well. In the meantime, 
supernatants of mock- infected or infected MDBK or HEp-2 cells were harvested, centrifuged 
at 5,000 rpm for 5 min (Eppendorf 5417R) to remove cell debris, transferred to a fresh tube 
and incubated at 56°C for 30 min to eliminate replication-competent RSV. Thus treated, 
supernatants were then transferred onto RV-infected MDBK cells (400 ml/well). Supernatants 
of RV-infected MDBK cells were harvested 2 days post infection and rabies virus titers were 
determined by limiting dilution and immunostaining as described above (2-7). 
 
2-13 Transfection of reporter plasmids and luciferase assay 
 
Reporter plasmids containing the luciferase gene under the control of the IFN-b  gene 
promoter/enhancer (p125Luc) or under the control of the PRDI domain containing the IRF-3 
binding sequence (p55CIBLuc), and a plasmid from which a dominant negative form of IRF-
3 is expressed (pEF-haIRF358-427) were kindly provided by Takashi Fujita, Kyoto, Japan. 
All transfection experiments were carried out on subconfluent 293 cells seeded into 35 mm 
dishes at least 12 hours prior to transfection (2x106 cells/dish). 1 mg of reporter construct 
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p125Luc and, when indicated, 1.5 mg of expression construct pEF-haIRF358-427 per dish were 
transfected using the FuGENE 6 transfection reagent. Ten hours post transfection, cells were 
trypsinized, resuspended, and seeded into 24-well plates using 4x105 cells/well. 24 hours post 
transfection, cells were infected with the indicated rBRSVs at an MOI of 0.2 (4x105 
cells/well) in serum-free DMEM. After an infection step of 90 min, cells were washed once 
with DMEM and then incubated in DMEM supplemented with 2.5% FCS. Cells were 
harvested 10 hours post infection or at indicated time points with 150-200 ml luciferase lysis 
buffer (20 mM Tris HCl pH [7.8], 2 mM DTT, 2 mM CDTA, 10% glycerol, 1% Triton X-
100; incubation 10 min at 37°C), followed by short centrifugation to remove unsoluble parts. 
Aliquots were then assayed for reporter gene activity in a luciferase assay. To rule out 
differences in gene activity due to varying amounts of transfected cells present in the sample, 
the protein content of each sample was determined in parallel using Coomassie Protein Assay 
Reagent.  
For experiments using poly I/C as trigger for IFN induction, 2x106 293 cells/ 35mm dish 
were mock- infected or infected with BRSV wt at an MOI of 0.25 as described above (one 35 
mm dish per amount of poly I/C). 14 hrs post infection cells were transfected with 1 mg 
p125Luc/35 mm dish using the FuGENE 6 transfection reagent. 24 hrs post infection, cells 
were again transfected with the indicated amounts of poly I/C using the FuGENE 6 
transfection reagent. 38 hrs post infection cells were harvested in 300 ml luciferase lysis buffer 
and luciferase activity was measured as described below. 
For experiments assaying the activities of the transcription factors IRF-3, NF-kB or AP-
1, 2x106 293 cells were transfected with 1 mg (p55CIBLuc, pAP-1Luc) or 0.5 mg (pNF-
kBLuc) of the indicated reporter construct using the FuGENE transfection reagent. 8 hrs later 
cells were trypsinized, seeded into 24-wells using 4x105 cells/well and infected with the 
indicated recombinant viruses at an MOI of 0.2. 14-16 hrs post infection cells were harvested 
in 120-150 ml luciferase lysis buffer and luciferase activity measured as described below. 
 
Luciferase assays were performed as follows. 20 ml of each cell lysate was mixed with 80 ml 
luciferase lysis buffer. 100 ml luciferase substrate buffer (20 mM tricine, 2.67 mM MgSO4, 
0.1 mM EDTA, 33.3 mM DTT, 1.07 mM MgCO3 x Mg(OH)2 x 5 H2O) supplemented with 
470 mM luciferin, 270 mM AcetylCoA, and 530 mM ATP was added automatically in the 
luminometer (Perkin Elmer Wallac GmbH) and light emission was measured as relative light 
units (RLU). 
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2-14 Detection of IRF-3 phosphorylation  
 
For western blot analysis of phosphorylated IRF-3, 2x106 293 cells were mock-infected or 
infected in suspension with the indicated RSVs at an MOI of 0.25-0.3 for 1 hour and then 
seeded into 6-well plates. 10 hours post infection, cells were harvested and nuclear extracts 
were prepared as follows. Cells were removed from the culture dish using PBS supplemented 
with 5 mM EDTA. Cell pellets were resuspended in 150 ml NP40 buffer (10 mM Hepes pH 
[7.9], 10 mM NaCl, 3 mM MgCl2, 0.5% NP40) and incubated on ice for 40 min. Afterwards, 
the cell suspension was checked for intact nuclei, followed by centrifugation at 7,000 rpm and 
4°C for 5 min (Eppendorf 5417R). Supernatants were kept as cytoplasmic extracts, and pellets 
containing the intact nuclei were washed once with cold PBS and stored at -20°C. Prior to 
SDS-PAGE, pellets were lysed with 100 ml cell lysis buffer containing 1% Triton X-100 and 
50 ml of each sample were mixed with 25 ml 3x SEB, incubated for 5 min at 95°C, and applied 
onto a large 10% polyacrylamide gel (Penguinä  Model P10DS, 20x20 cm). The 
electrophoresis (80 V, 16-20 h run) was stopped when the 43 kD marker band was migrated 
to the lower end of the gel. Proteins were transferred and the membrane probed with an 
antibody recognizing human IRF-3 (1:1000 in PBS-T) as described above (2-9). 
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RESULTS 
 
1 PNEUMOVIRUS NS PROTEINS COOPERATIVELY 
CONFER VIRAL RESISTANCE TO IFN 
 
 
Construction of recombinant RVs expressing BRSV NS proteins  
 
BRSV NS deletion mutants that lack either one or both NS genes show approximately equal 
degrees of sensitivity against IFN-mediated responses suggesting that both NS proteins are 
required to counteract antiviral mechanisms. To verify the obligatory cooperative function of 
NS1 and NS2 and to determine whether the two NS proteins are sufficient to protect an 
unrelated virus or whether additional factors are needed, we generated rRVs expressing either 
NS1 (VB bNS1) or NS2 (VB bNS2). For detection purposes, C-terminally tagged BRSV NS 
proteins were generated, with NS1 carrying additional 27 nt corresponding to an internal 
region of the influenza virus hemagglutinin (HA) protein, and NS2 carrying additional 24 nt 
corresponding to the synthetic FLAG peptide. The additional gene was introduced between 
the G and L genes of the attenuated SAD VB, as previously described for successful 
expression of other genes (Fig. 9; 66,82). Recombinant viruses were recovered from cDNA in 
BSR T7/5 cells transfected with plasmids expressing the RV N, P, and L genes. Synthesis of 
the NS proteins was monitored by western blotting (see Figs. 11C, 14B), and no obvious 
adverse effect on infectious titers and growth characteristics of the recombinants in BSR cells 
was observed (data not shown). 
  
Fig. 9: Organization of recombinant RVs expressing tagged BRSV NS genes. Tagged BRSV NS1 or BRSV 
NS2 open reading frames (NS1ha or NS2fl, respectively) were inserted at a unique SmaI site located between the 
RV G and L genes. 
 
                                                                    RESULTS  
     45 
BRSV NS1 and NS2 cooperatively enhance IFN resistance of RV 
 
To study the activity of the expressed BRSV NS proteins, Vero cells were infected at an MOI 
of 5 with parental RV (VB wt) or with each of the recombinants, or were co- infected with 
both recombinants, VB bNS1 and VB bNS2, at an MOI of 2.5 each. Directly after infection, 
cells were treated with increasing amounts of recombinant IFN-a A/D and the production of 
infectious RV titers was analysed 2 days post infection. Growth of the parental RV and of 
NS1 or NS2 protein-expressing viruses from single infections was similarly affected (Fig. 
10A). On application of 50 IU of IFN-a titers dropped by approximately 1 log unit and then 
further decreased very slowly with increasing IFN amounts, indicating either a weak IFN 
response of Vero cells or a high intrinsic resistance of RV to IFN-mediated responses in Vero 
cells. In cells co- infected with NS1 and NS2-expressing viruses, however, protection of virus 
replication could be shown. Virus titers remained significantly higher than in single infections 
and decreased slowly in a dose-dependent manner. Similar results were also obtained when 
viral protein expression was monitored. Only in cells coinfected with both recombinants, viral 
protein synthesis was maintained in the presence of up to 150 IU of IFN-a (Fig. 11A).   
 
Fig. 10: IFN resistance in cells coinfected with RVs expressing BRSV NS1 and NS2. Vero cells (A) or 
MDBK cells (B) were infected with wild-type VB, VB bNS1, or VB bNS2, or coinfected with VB bNS1 and VB 
bNS2. Immediately after infection, cells were treated with the indicated amounts of IFN-a A/D. Infectious virus 
titers were determined 2 days post infection. Results represent the mean values of at least four independent 
experiments, with error bars indicating standard deviations.  
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In parallel experiments performed in MDBK cells, parental RV and the NS-expressing 
recombinants replicated to slightly lower titers in untreated MDBK cells than in Vero cells. In 
contrast to Vero cells, treatment with IFN more dramatically reduced infectious titers of wt 
RV and of NS-expressing viruses from single infections. An immediate reduction in 
infectious titers by 3 log units indicated a highly effective IFN-mediated cell response. 
However, in cells co- infected with viruses expressing NS1 and NS2 proteins, virus replication 
was completely protected against IFN until more than 150 IU of IFN was applied (Fig. 10B). 
These results were reflected by the analysis of RV protein synthesis. In untreated cells, all 
recombinants produced substantial and comparable amounts of RV proteins whereas in IFN-
treated cells, only coinfections with VB bNS1 and VB bNS2 led to substantial protein 
synthesis until more than 150 to 200 IU was applied (Fig. 11B). These results confirm that the 
two BRSV NS proteins are required and sufficient for exerting the observed IFN antagonist 
activity. In addition, they show that both NS proteins are able to confer resistance to IFN-
mediated antiviral response not only to BRSV but also to another, unrelated rhabdovirus.  
 
 
 
Fig. 11: RV protein synthesis in IFN challenge experiments. Vero (A) or MDBK cells (B) were infected as 
described in Fig. 8, and cultures were treated with 0, 50, 150, 500 and 2,000 IU (A) or 0, 50, 150, 175, 500 IU of 
IFN-a (B). Cells were harvested 2 days post infection and extracts were analysed by western blot. RV N protein 
was detected using a serum raised against RV (S50). (C) Western blot analysis of BRSV NS protein expression 
in Vero cells infected with VB bNS1 and VB bNS2. Cells were treated with 0, 50 or 150 IU of IFN-a directly 
after seeding, and harvested 2 days post infection. NS1 protein was detected using an antibody recognizing the 
HA-tag (Y-11). For detection of NS2, an antibody recognizing the FLAG-tag (M2) was used.  
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To rule out the possibility that the addition of the HA- or FLAG-tag to NS1 and NS2, 
respectively, influences their function(s) in the viral life cycle, recombinant BRSVs 
expressing either NS1ha or NS2fl were generated (BRSV ha and BRSV fl, respectively; Fig. 
12A). Both recombinant BRSVs were recovered by cotransfection of BSR T7/5 cells with 
BRSV full- length cDNA with support plasmids encoding BRSV N, P, L, and M2 genes as 
described in 2-4, and synthesis of the tagged NS proteins was monitored by Western blotting 
(Fig. 12B).  
 
 
 
Fig. 12: IFN resistance of rBRSVs expressing tagged BRSV NS genes is not altered.  (A) Genomes of 
rBRSV expressing NS1ha (BRSV ha) or NS2fl (BRSV fl). (B) Western blot analysis of cell lysates from Vero 
cells infected with BRSV ha and BRSV fl. NS1ha was detected using an antibody recognizing the HA-tag (Y-
11). NS2fl was recognized by an antibody raised against the synthetic FLAG epitope (M2). (C) Vero or MDBK 
cells infected at an MOI of 0.1 with BRSV wt, BRSV ha, or BRSV fl were incubated with the indicated amounts 
of recombinant IFN-a directly after seeding. Infectious titers were determined 3 days post infection. Results are 
shown as fold reduction in viral titer and represent the mean values of two independent experiments.  
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IFN challenge experiments were performed in Vero and MDBK cells to determine the 
protective capacity of the modified NS proteins towards exogenous IFN. As expected, no 
difference in IFN resistance was observed for BRSV ha or BRSV fl when compared with wt 
BRSV (Fig. 13). We therefore conclude that the addition of a protein tag to either NS protein 
does not compromise its IFN antagonist function in the context of a viral infection. 
 
 
HRSV and PVM NS proteins protect RV from IFN-induced responses 
 
Having established an assay system based on rRV to monitor IFN resistance function of a 
given protein we addressed the question whether the NS proteins of HRSV and PVM also 
possess IFN antagonist activity and whether this activity is comparable to that observed with 
BRSV NS proteins. RVs expressing either HRSV NS1 or NS2 (VB hNS1 and VB hNS2, 
respectively) or PVM NS1 or NS2 (VB mNS1 and VB mNS2, respectively) were generated 
by insertion of the additional gene between the G and L genes of the infectious SAD VB full-
length antigenomic cDNA clone (Fig. 13A). Efficient expression of either NS protein was 
confirmed by Western blot analysis (Fig.13B). 
 
 
 
 
 
 
Fig. 13A:  rRVs expressing HRSV and PVM NS genes. Genome organization of rRV containing HRSV or 
PVM NS open reading frames between the RV G and L genes. For detection purposes, an HA-tag was added at 
the C-terminus of the PVM NS1 gene, at the C-terminus of the PVM NS2 gene, a FLAG-tag was added. No tag 
was added to either HRSV NS gene. 
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Fig. 13B:  rRVs expressing HRSV and PVM NS genes. Western blot analysis of RVs expressing HRSV (h) 
and PVM (m) NS genes. BSR cells were infected at an MOI of 1, and 3 days post infection cell extracts were 
harvested. HRSV NS1 and NS2 proteins were detected using a serum raised against a C-terminal peptide of NS1 
that cross-reacts with NS2 (a-IC/C; kindly provided by J.A. Melero, Spain). PVM and BRSV NS1 were detected 
with antibody Y-11 recognizing the HA-tag. PVM and BRSV NS2 were detected with an antibody recognizing 
the FLAG-epitope (M2). 
 
 
For demonstration of IFN-antagonistic activity of the expressed pneumovirus proteins, 
infection experiments were performed in MDBK cells, as replication of RV in these cells is 
highly sensitive to exogenous IFN. Cells were infected with parental RV (VB wt) or with 
each recombinant at an MOI of 5 or co-infected with both recombinants VB hNS1 and VB 
hNS2 or VB mNS1 and VB mNS2 at an MOI of 2.5 each. Immediately after infection, the 
cultures were treated with increasing amounts of recombinant IFN-a A/D, and the production 
of infectious RV was analysed 2 days post infection. Upon addition of 50 IU of IFN-a, 
infectious titers of wt RV and of NS-expressing viruses from single infections dropped by 3 
log units, confirming the highly effective IFN-stimulated antiviral response in MDBK cells 
(Fig. 14). However, in cells co-expressing hNS1 and hNS2 protection of virus replication in 
cells treated with up to 150 IU of IFN-a could be shown. Virus titers remained significantly 
higher than in single infections and decreased slowly in a dose-dependent manner. This 
protection of virus replication in the presence of IFN-a was comparable to the degree of 
protection observed in MDBK cells infected with the previously described rRVs expressing 
BRSV NS proteins (Fig. 14A). Co-expression of the PVM NS proteins, mNS1 and mNS2, 
also led to an increase in IFN resistance of RV, albeit to a somewhat lesser extent than co-
expression of the BRSV NS proteins (Fig. 14B) in that replication of RV was protected only 
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up to 100 IU of IFN-a. Thus, the NS proteins of HRSV and PVM are also able to antagonize 
IFN-mediated antiviral responses and do so only when expressed together. 
 
 
 
Fig. 14: HRSV and PVM NS proteins confer IFN resistance to RV.  (A) MDBK cells were infected with VB 
wt, VB hNS1 (H1), VB hNS2 (H2), or coinfected with VB hNS1 and VB hNS2 (H1+H2). As positive control, 
cells were also coinfected with VB bNS1 and VB bNS2 (B1+B2). Indicated concentrations of recombinant IFN-
a were added immediately after seeding, and virus titers were determined 2 days post infection. Error bars 
indicate standard deviation. (B) Infection of MDBK cells with VB mNS1 (M1) or VB mNS2 (M2), or 
coinfection with VB mNS1 and VB mNS2 (M1+M2) as described above. Results represent the mean values of 
three independent experiments, with error bars indicating standard deviations. 
 
 
HRSV and BRSV NS proteins are able to cooperate  
 
The capacity of all pneumovirus NS proteins to protect against IFN-induced effects prompted 
us to further investigate whether combinations of BRSV and HRSV or BRSV and PVM NS 
proteins are also functional in mediating IFN resistance. MDBK cells were infected with four 
pairs of recombinant viruses expressing single NS proteins from HRSV (h), BRSV (b) or 
PVM (m), namely VB bNS1 and VB hNS2, VB hNS1 and VB bNS2, VB bNS1 and VB 
mNS2, and VB mNS1 and VB bNS2, and treated with IFN as described above. Whereas no 
PVM NS protein was found functional in combination with the complementing BRSV NS 
protein (Fig. 15B), both HRSV/BRSV pairs (bNS1/hNS2 and hNS1/bNS2) were able to 
increase the IFN resistance of RV (Fig. 15A). However, while co-expression of BRSV NS1 
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and HRSV NS2 was as effective as the two homologous combinations, the inverse 
combination of HRSV NS1 and BRSV NS2 did not rescue viral growth in the presence of 
more than 50 IU of IFN-a, as observed in several independent experiments. Nevertheless, the 
cooperativity of HRSV and BRSV NS proteins in IFN escape strongly suggests that they have 
identical function(s) and similar target proteins whereas the highly dissimilar NS proteins of 
PVM were unable to cooperate with their BRSV counterparts but might still share a similar 
mechanism to antagonize IFN-induced cell responses. 
 
Fig. 15: Combinations of HRSV and BRSV NS proteins render RV IFN resistant. (A) MDBK cells were 
coinfected with various combinations of rRVs expressing BRSV (b) or HRSV (h) NS1 or NS2. Recombinant 
IFN-a was added immediately after seeding, and viral titers were determined 2 days post infection. Results 
represent the mean values of three independent experiments (VBmNS1+VBbNS2 and VBbNS1+VBmNS2 two 
independent experiments) with error bars indicating standard deviation. (B) Infection of MDBK cells with 
combinations of recombinant RVs expressing BRSV or PVM nonstructural genes. Results represent the mean 
values of three independent experiments (VBmNS1+VBbNS2 and VBbNS1+VBmNS2 two independent 
experiments) with error bars indicating standard deviation. 
 
 
A recombinant RV expressing both BRSV NS proteins  
 
Since we could show that any IFN antagonist activity requires the presence of both NS 
proteins, a recombinant RV expressing both NS proteins of BRSV (VB 2+1) was 
subsequently generated allowing us to circumvent the ambiquities related to co-infections, 
such as a low percentage of cells expressing both NS proteins or varying protein expression 
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levels, when studying NS protein function. In a first step, an RV stop-restart sequence was 
introduced between the NS2 and the NS1 gene of BRSV, then both genes were inserted 
between the G and L gene of SAD VB (Fig. 16A). The resulting recombinant (VB 2+1) was 
recovered from cDNA as described previously (see section 2-6) and synthesis of both NS 
proteins was monitored by Western blotting (Fig. 16B). Even though two additional genes 
were inserted into the RV genome, the growth properties of VB 2+1 were not significantly 
influenced in BSR cells compared to wt VB (data not shown). However, as expected, VB 2+1 
was substantially more IFN resistant than VB wt when challenged with exogenous IFN-a 
A/D, with 500 IU reducing viral titers only about 1 log unit (Fig. 16C). The possibility to 
generate recombinant RVs expressing several additional proteins without inhibition of virus 
replication will provide a useful tool to study IFN antagonist function of various (pneumo-) 
virus proteins in vitro and in vivo. 
 
 
Fig. 16: Recombinant RV expressing both BRSV NS genes. (A) Genome organization of an rRV containing 
BRSV NS1 and NS2 open reading frames between the RV G and L genes (VB2+1). (B) Western blot analysis of 
NS protein expression in VB2+1 infected BSR cells using a-HA antibody to detect NS1ha, a-FLAG antibody to 
detect NS2fl, and S50 serum to detect RV N and P protein. (C) IFN resistance of RV expressing both NS 
proteins of BRSV. MDBK cells were infected with VB wt (solid square), or VB2+1 (open square), and indicated 
amounts of recombinant IFN-a were added. Virus titers were determined 2 days post infection. Results represent 
the mean value of two independent experiments. 
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2 INVOLVMENT OF PNEUMOVIRUS NS PROTEINS 
IN DETERMINING VIRAL HOST RANGE 
 
 
Chimeric BRSVs expressing HRSV NS genes  
 
To investigate NS protein function in its more natural pneumovirus context rather than in the 
heterologous rabies virus, we generated recombinant BRSVs possessing either one or both NS 
genes from HRSV instead of the homologous NS gene(s) (rBRSV h1, rBRSV h2, or rBRSV 
h1/2; Fig. 17). cDNAs were obtained by RT-PCR from Vero cells infected with HRSV strain 
Long and were used to replace the BRSV NS genes as described in 2-5. Recombinant viruses 
were recovered by co-transfection of BSR T7/5 cells with the BRSV full- length cDNAs with 
support plasmids encoding BRSV N, P, L, and M2 genes described previously (8). Virus 
stocks were produced in Vero cells, as these lack an intact IFN-a/b  system (31,97), and 
expression of the NS proteins were monitored by Western blot analysis (Fig. 18A).  
 
 
 
Fig. 17: Construction of chimeric rBRSVs expressing HRSV NS genes. The locations of the protein-encoding 
frames (shaded bars ) are shown relative to the viral genome (vRNA, black bar). In the enlargement, the 
organization of BRSV wild-type and the recombinant BRSVs carrying one or both HRSV nonstructural proteins, 
BRSV h1, BRSV h2, and BRSV h1/2, are depicted. Leader RNA is marked by diagonal hatching.  
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The a-IC/C antibody (kindly provided by J.A. Melero) was used for detection of HRSV NS 
proteins. a-IC/C serum was raised against a C-terminal peptide of HRSV NS1 and shows 
crossreactivity with HRSV NS2 and BRSV NS2 (J.A. Melero, personal communication). 
Unfortunately, the HRSV NS2 protein synthesized in BRSV h2 infected cells could not be 
detected (Fig. 18A). Therefore, RT-PCR was performed and the presence of virus-encoded 
HRSV NS2 mRNA in BRSV h2 infected cells was verified (data not shown). In addition, 
immunofluorescent staining of HRSV NS2 in BRSV h2 infected cells also gave a distinct 
signal (see Fig. 37). RT-PCR followed by sequencing of the amplified NS2 coding region will 
show whether BRSV h2 carries a mutation in its C-terminus responsible for the failure to 
detect the HRSV NS2 protein by Western blotting with a-IC/C. 
 
 
 
Fig. 18: Analysis of chimeric BRSVs expressing HRSV NS genes. (A) Western Blot analysis of HRSV NS 
protein synthesis in Vero cells infected with chimeric BRSVs. NS proteins were detected using a-IC/C antibody 
recognizing HRSV NS proteins and BRSV NS2 (kindly provided by J.A. Melero, Spain). (B), (C) Growth 
kinetics of chimeric BRSV h1, BRSV h2, BRSV h1/2, and wild-type BRSV in Vero (B) and MDBK cells (C). 
Cells were infected at an MOI of 0.1 and virus was harvested at indicated time points. Results represent the mean 
values of three independent experiments, error bars indicate standard deviation.   
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   Growth of BRSV h1/2 is attenuated only in bovine cells   
 
The growth behaviour of all three chimeric BRSVs (BRSV h1, BRSV h2, and BRSV h1/2) in 
IFN-negative Vero cells was indistinguishable from that of wild-type BRSV. All viruses 
produced infectious titers of about 3x105 PFU 2 days after infection at an MOI of 0.1 (Fig. 
18B). The identical growth suggests that the HRSV NS proteins are able to entirely fulfill the 
function(s) of their bovine counterparts important for efficient RNA synthesis in Vero cells. 
Next, a cell line of bovine origin, MDBK, was used which harbors an intact IFN system. In 
this cell line that optimally supports the growth of wt BRSV, growth of BRSV h1/2 was 
markedly attenuated. Whereas wt BRSV reached titers of 7x105 PFU after 3 days, BRSV h1/2 
grew only up to 1x104 PFU (Fig. 18C). In contrast, chimeric BRSV h1 and BRSV h2 were 
less attenuated with BRSV h1 reaching titers similar to wild-type BRSV, whereas BRSV h2 
growing to slightly lower titers of 1x105 PFU 3 days post infection (Fig. 18C). This indicates 
that the presence of at least one NS protein from BRSV can overcome the attenuated growth 
phenotype mediated by both HRSV NS proteins, as observed with BRSV h1/2 in bovine cells.  
 
 
Fig. 19: Growth of BRSV h1/2 is attenuated in bovine cells. Vero (A), HEp-2 (B), MDBK (C) or Klu cells 
(D) were infected with BRSV wt or BRSV h1/2 at an MOI of 0.1. Virus was harvested at indicated time points. 
Results represent the mean values of two independent experiments. Bars show range of individual data points. 
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To confirm the attenuated growth of BRSV h1/2 in bovine MDBK cells (see also Fig. 19C) 
another bovine cell line isolated from embryonic calf lung tissue, Klu, was subsequently used. 
In this cell line, the attenuation of BRSV h1/2 was even more pronounced. Here, BRSV wild-
type grew to highest titers of 1.5x106 PFU 2 days post infection, whereas the chimeric BRSV 
h1/2 was barely able to grow, reaching titers of only 3x102 PFU (Fig. 19D). In constrast, in a 
human cell line, HEp-2, growth characteristics of wt BRSV and BRSV h1/2 were again 
comparable (Fig. 19B). Both viruses reached similar titers of 3x104 PFU after 3 days. This 
indicates that in the context of an IFN-competent human cell system, the HRSV NS proteins 
may be at least an adequate substitute for their counterparts in BRSV, whereas in bovine cell 
IFN systems, they are obviously less efficient. 
 
 
 
IFN antagonistic activity is host cell specific 
 
Additional stimulation of infected cells with increasing doses of exogenous recombinant IFN-
a was then used to directly challenge the protective capacity of HRSV and BRSV NS proteins 
to cellular IFN-induced responses in cell lines of different origin. Vero cells cannot produce 
IFN-a/b , yet they are able to mount an effective antiviral response when exogenous IFN is 
added (31,97). In Vero cells infected with BRSV or BRSV h1/2, the replication of both 
viruses was largely resistant to high IFN doses (Fig. 20A). Only after application of more than 
5,000 IU of IFN-a was an approximately 10-fold reduction in infectious titers observed. In 
the bovine MDBK cells, resistance of BRSV wt to IFN-a was even more pronounced than in 
Vero cells. After application of 10,000 IU of IFN-a, virus titers were only five-fold reduced 
compared to the untreated control. In striking contrast, BRSV h1/2 showed a marked and 
dose-dependent sensitivity towards the IFN-induced antiviral response of MDBK cells, with 
5,000 IU of IFN-a reducing viral titers about 6-fold and 10,000 IU causing a 80-fold 
reduction (Fig. 20B). Thus, while IFN resistance of BRSV h1/2 in primate Vero cells is 
comparable to that of wt BRSV, BRSV h1/2 is not able to thoroughly counteract the IFN-
induced antiviral response in cells of bovine origin. On the contrary, in the  human HEp-2 cell 
line which is derived from a human nasopharyngeal carcinoma, BRSV h1/2 was more 
effective in counteracting the IFN-induced antiviral state than wild-type BRSV. Although in 
untreated HEp-2 cells growth of both viruses was similar (see Fig.  19B), BRSV h1/2 was 
superior to wild-type BRSV in coping with the effects of exogenous IFN (Fig. 20C). The 
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addition of 10,000 IU of IFN-a led to an approximately 10-fold reduction in BRSV h1/2 
titers, whereas the same dose reduced the yield of wt BRSV 100-fold. These results indicate 
that the NS proteins of BRSV and HRSV are adapted to optimally counteract the cellular IFN 
responses of their natural host. 
 
 
 
Fig. 20: IFN resistance of BRSV h1/2 is cell type dependent. Vero (A), MDBK (B), or HEp-2 cells (C) were 
infected at an MOI of 0.1 with the indicated viruses. Recombinant IFN-a A/D was added to concentrations up to 
10,000 U/ml directly after seeding. Virus titers were determined 3 days post infection and results are shown as 
reduction of viral titers (viral titers obtained without IFN treatment were set to 1). Results represent the mean 
value of two independent experiments with bars showing the range of the individual data points.  
 
 
Chimeric BRSVs expressing PVM NS genes 
 
Having shown that the NS proteins of PVM are able to confer IFN resistance to an unrelated 
rhabdovirus (Fig. 14), we were interested to see whether these only very distantly related 
PVM NS genes are also functional in a BRSV background. BRSV recombinants were 
therefore generated expressing either PVM NS1 (BRSV m1) or NS2 (BRSV m2), or both 
PVM NS proteins (BRSV m1/2; Fig. 21) as described in Materials and Methods (2-5). 
Recombinant viruses were recovered as described before, followed by production of virus 
stocks in Vero cells. Expression of the PVM and BRSV NS proteins was verified by Western 
blotting (Fig. 22A). 
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Fig. 21: Construction of chimeric rBRSVs expressing PVM NS genes. The locations of the protein-encoding 
frames (shaded bars) are shown relative to the viral genome (vRNA, black bar). In the enlargement, the 
organization of BRSV wild -type and the recombinant BRSVs carrying one or both PVM nonstructural proteins, 
BRSV m1, BRSV m2, and BRSV m1/2, are depicted. Leader RNA is marked by diagonal hatching.  
 
 
BRSV m1/2 is attenuated in human and bovine cells 
 
Growth properties of the different chimeric BRSVs were first analysed in Vero cells that do 
not possess an intact IFN system. In comparison with the wild-type BRSV, BRSV m1 and 
BRSV m1/2 were slightly attenuated and grew to titers of at most 1x105 PFU/ml, similar to 
viral titers obtained with the double deletion mutant BRSV D1/2 lacking both NS genes (Fig. 
22B). This suggests that, in contrast to the HRSV NS proteins (see Fig. 19), the NS proteins 
of PVM cannot take over the function of their bovine counterparts in viral replication and/or 
RNA synthesis. In IFN-a challenge experiments, BRSV D1/2 was, as expected, highly 
sensitive to IFN-induced cellular responses even in the presence of low amounts of IFN-
a (Fig. 22C). However, BRSV m1/2 was significantly resistant to IFN treatment with 5,000 
IU reducing titers only about 20-fold demonstrating that the NS proteins of PVM are able to 
confer IFN resistance in the context of a pneumovirus infection (Fig. 22C). Interestingly, both 
BRSV m1 and BRSV m2 (expressing one BRSV and one PVM NS protein) were highly 
sensitive to exogenously added IFN with 5,000 IU resulting in an approximately 1,000-fold 
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reduction. This demonstrates that the NS proteins of BRSV and PVM are indeed not able to 
cooperate in mediating IFN resistance, as was already observed in experiment using 
recombinant RVs (Fig. 22C, see also Fig. 15B). 
 
 
 
 
Fig. 22: Analysis of chimeric rBRSVs expressing PVM NS genes. (A) Western blot analysis of PVM NS 
protein synthesis in infected Vero cells. NS1 was detected with an antibody recognizing the HA-tag (Y-11), NS2 
was detected using an antibody recognizing the synthetic FLAG-tag (M2). The BRSV NS2 protein was detected 
using a-IC/C (kindly provided by J.A. Melero, Spain). (B) All recombinant BRSVs expressing one or both PVM 
NS proteins are attenuated. Vero cells were infected with the indicated viruses at an MOI of 0.1. At the indicated 
time points virus was harvested and titers were determined by limiting dilution. Results show the mean values of 
two independent experiments. Bars show the range of individual data points. (C) BRSV m1/2 is IFN resistant. 
Vero cells were infected at an MOI of 0.1 with the indicated viruses. Recombinant IFN-a A/D was added to 
concentrations up to 5,000 U/ml directly after seeding. Virus titers were determined 3 days post infection. 
Results show the mean value of two independent experiments with bars indicating the range of individual data 
points. 
 
 
To investigate whether BRSV m1/2 would benefit from its capacity to antagonize IFN-
induced cellular responses compared to the double deletion mutant BRSV D1/2, growth 
properties of BRSV m1/2 were analysed in IFN competent cells. In bovine MDBK cells, 
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growth of BRSV m1/2 was severely attenuated compared to wt BRSV with titers reaching 
only 1x103 PFU/ml 2 days post infection. However, BRSV m1/2 multiplied significantly 
better than BRSV D1/2 (Fig. 23A). In human HEp-2 cells, BRSV m1/2 was also attenuated 
with titers of 3x103 PFU/ml 2 days post infection whereas wt BRSV grew up to 5x104 
PFU/ml (Fig. 23B). However, BRSV m1/2 grew again to higher titers than the double 
deletion mutant BRSV D1/2 demonstrating that replication of BRSV m1/2 is improved by the 
ability of the PVM NS proteins to interfere with the cellular antiviral state.  
 
 
 
Fig. 23: Growth of BRSV m1/2 is attenuated in IFN-competent cells. MDBK (A) or HEp -2 cells (B) were 
infected at an MOI of 0.1 with BRSV wt, BRSV m1/2, or BRSV D1/2. Virus was harvested at the indicated time 
points, and titers were determined by limiting dilution. Results represent the mean values of two independent 
experiments. Bars show the range of individual data points. 
 
 
I then wanted to investigate whether BRSV m1/2 would fare better in the context of a murine 
IFN system, as this is the case for the HRSV NS proteins in a human IFN system. However, it 
was not possible to analyse the growth properties of BRSV and BRSV m1/2 in a variety of 
murine cell lines since BRSV was found to infect and propagate in murine cells only very 
poorly with titers reaching rarely up to 1x103 PFU/ml. This observation is consistent with the 
fact that infection of laboratory mice with BRSV does not yield any symptoms or a detectable 
viral replication. In contrast, infection of mice with HRSV leads to the development of light 
symptoms indicating that HRSV must have a more efficient means to enter and/or propagate 
in murine cells than BRSV.  
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Since no reverse genetics system is presently available for PVM, other approaches are 
necessary to study PVM NS protein function. The replacement of the BRSV surface proteins 
F and G with their counterparts from HRSV might improve entry of BRSV into murine cells. 
Construction of such “double chimeric” viruses (e.g. BRSV m1/2 FhGh) should then allow us 
to analyse the IFN resistance capacity of the PVM NS proteins in their natural environment of 
a murine cell and to determine whether the NS proteins of PVM are also involved in 
determining host range. 
 
 
 
3 BRSV NS PROTEINS ARE REQUIRED FOR 
INHIBITION OF IFN-b INDUCTION 
 
ISG expression is not upregulated in BRSV wt infected cells 
 
As demonstrated previously, the presence of both NS proteins increases resistance of BRSV 
or an unrelated rhabdovirus against the antiviral action of IFN. However, the molecular events 
leading to the observed IFN resistance are unclear. As a first step to elucidating the 
underlaying mechanism, I was interested to see whether cells harboring an intact IFN system 
would establish an antiviral state after infection with wild-type BRSV or the NS double 
deletion mutant. For that purpose, bovine MDBK cells and human HEp-2 cells were infected 
with wild-type BRSV, BRSV D1/2, and the chimeric BRSV h1/2 at an MOI of 0.2. As 
positive control for successful establishment of an IFN-induced antiviral state, mock- infected 
cells were treated with 2,000 IU/ml of recombinant IFN-a A/D directly after seeding. Cells 
were harvested 24 hrs post infection and equal amounts of whole cell extract were subjected 
to SDS-PAGE. As internal loading control, the membranes were probed with an antibody 
recognizing the “proliferating cell nuclear antigen” (PCNA), a marker protein for cell 
proliferation not influenced by the addition of exogenous IFN-a to both MDBK and HEp-2 
cells (Fig. 24).   
In HEp-2 cells, infection with BRSV D1/2 led to increased expression of IFN stimulated 
genes (ISGs), namely STAT2, PKR and IRF-9/p48 (25) indicating that production of IFN and 
the subsequent signaling pathway leading to the upregulation of ISGs was successfully 
triggered (Fig. 24A/B). To our surprise, however, ISG levels were not upregulated in wt 
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BRSV infected cells suggesting that in the presence of the two NS proteins the pathway 
leading to the upregulation of ISGs is blocked. Infection of MDBK cells with the double 
deletion mutant and wt BRSV gave similar results showing increased levels of STAT2 and 
p48 in BRSV D1/2 infected cells but not in MDBK cells infected with the wild-type BRSV 
(Fig. 24A/B). However, the antibody recognizing PKR did not give a specific signal when 
cell extracts from MDBK cells were used.  
 
 
Fig. 24: ISG expression in infected MDBK and HEp-2 cells. (A,B) MDBK and HEp-2 cells were infected 
with the indicated viruses at an MOI of 0.2. 24 hrs post infection, cells were harvested, and whole cell extracts 
were subjected to SDS-PAGE. As internal control for upregulation of ISGs, mock-infected cells were treated 
with 2000 U/ml of recombinant IFN-a A/D. After Western blotting, membranes were probed with antibodies 
recognizing STAT2, p48 (IRF-9), and PCNA as loading control. (C) MDBK and HEp-2 cells were infected with 
HRSV Long at an MOI of 0.2, cells were harvested 24 hrs post infection, and a Western blot was performed as 
described in (A).  
 
 
Interestingly, MDBK or HEp-2 cells infected with the chimeric virus expressing the HRSV 
NS genes, BRSV h1/2, also showed increased levels of STAT2, PKR and p48 (Fig. 24A/B) 
demonstrating that, in contrast to the BRSV NS proteins, the closely related HRSV NS 
proteins are not able to prevent upregulation of ISGs (Fig. 24A). To confirm this finding, both 
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cell lines were infected with the parental HRSV strain Long and assayed for upregulation of 
STAT2. Indeed, infection of cells with HRSV led to increased STAT2 levels (Fig. 24C) 
suggesting that the HRSV NS proteins do not have the capacity to block upregulation of ISGs 
in vitro.  
 
In immunofluorescent studies performed in parallel, infected MDBK and HEp-2 cells were 
fixed 2 days post infection and stained with antibodies recognizing BRSV nucleoprotein and 
STAT2 as described in Materials and Methods (2-10). Cells treated with exogenous IFN-a 
displayed a clear increase in STAT2 levels compared to the untreated control (Fig. 25). 
However, a similar increase was not observed in cells infected with wild-type BRSV 
indicating that even 2 days after infection, upregulation of ISGs is still blocked. In contrast, 
infection with BRSV D1/2 or BRSV h1/2 led to upregulated STAT2 levels even in non-
infected cells in the vicinity of productively infected cells demonstrating the establishment of 
an antiviral state even in non- infected cells in response to viral infection. 
 
 
Fig. 25: Immunofluorescent staining of STAT2 in infected cells. MDBK (A) and HEp-2 cells (B) were 
infected with the indicated viruses at an MOI of 0.2. At 48 hrs post infection cells were fixed with 3% 
paraformaldehyde and incubated with STAT2 antibody and an antibody recognizing the BRSV N protein (79N; 
kindly provided by J.A. Melero) 
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IFN is not produced in BRSV wt infected cells  
 
To investigate IFN production in BRSV wt infected cells, an assay system was used based on 
the high sensitivity of rabies virus (RV) replication to IFN in MDBK cells. Supernatants of 
wild-type BRSV, BRSV h1/2, BRSV D1/2 or mock- infected MDBK and HEp-2 cells were 
harvested 24, 48 and 72 hrs post infection and incubated at 56°C for 30 minutes to inactivate 
replication-competent virus. These supernatants were then added onto MDBK cells previously 
infected with RV at an MOI of 5, and RV titers were determined 2 days post infection. 
Supernatants from mock- infected MDBK and HEp-2 cells allowed RV to replicate to titers up 
to 107 PFU/ml whereas supernatants taken from cells infected with BRSV D1/2 or BRSV h1/2 
were able to suppress RV replication about 3 log units demonstrating the presence of active 
IFN (Fig. 26). However, supernatants from wild-type BRSV infected cells did not influence 
RV titers significantly, indicating that the presence of both bovine NS proteins in the 
homologous BRSV inhibits production and/or secretion of IFN.  
 
 
Fig. 26: IFN production in infected MDBK and HEp-2 cells. MDBK or HEp -2 cells were mock-infected or 
infected with the indicated viruses at an MOI of 0.2. Cell supernatants were harvested 24, 48, and 72 hrs post 
infection and transferred onto RV-infected MDBK cells. RV titers were determined 2 days post infection. 
Results represent the mean values of two independent experiments. 
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BRSV wt inhibits induction of the IFN-b gene promoter 
 
To correlate IFN production with IFN promoter activity, a reporter gene construct was used 
harboring the luciferase gene under the control of the IFN-b gene promoter/enhancer 
(p125Luc; kindly provided by T. Fujita, Kyoto, Japan). First, the kinetics of IFN induction in 
BRSV infected cells were examined. Since the transfection efficiency of MDBK cells is 
extremely low (1-5%) and viral stocks obtained for the double deletion mutant BRSV D1/2 do 
not yield more than 1x105 ffu/ml, reporter assays requiring the presence of transfected and 
simultaneously infected cells are not feasible. We therefore selected a cell line that allows 
transfection efficiencies of up to 95%, as is the case in human 293 cells, so that infections 
using low MOIs (at most MOI=0.3) represent the only limiting factor of this assay. 293 cells 
were transiently transfected with p125Luc followed by mock-infection or infection with 
BRSV D1/2 (MOI 0.3) 24 hrs post transfection. At 0, 2, 4, 6, 8, and 10 hours post infection 
cells were harvested and luciferase activity was measured. In BRSV D1/2- infected cells, 
luciferase activity was first detected around 3 hours post infection with a maximal 25-fold 
induction of the IFN-b  gene promoter found at 8 to 10 hrs post infection indicating a very fast 
and efficient response in 293 cells to viral infection (Fig. 27A).  As a next step, 293 cells were 
transfected with p125Luc followed by infection with wild-type BRSV, BRSV D1/2, BRSV 
h1/2 or HRSV Long at an MOI of 0.25, and 10 hours post infection cells were harvested and 
luciferase activity was measured. While a strong, 20-fold induction of luciferase activity was 
observed in BRSV D1/2 infected cells, and a 16.5- and 15.5-fold induction in cells infected 
with BRSV h1/2 and HRSV, respectively, only a slight induction of the IFN-b 
promoter/enhancer of about 3.5-fold compared to mock-infected cells was found in wild-type 
BRSV infected cells (Fig. 27B). Taken together these results indicate that the NS proteins of 
BRSV are able to mediate resistance to antiviral effects of exogenous IFN as well as to 
diminish virus- induced activation of the IFN-b  promoter in cultured cells.  
To demonstrate that IRF-3 is involved in the induction of the IFN-b  gene promoter in 
BRSV-infected 293 cells, p125Luc and a plasmid expressing a dominant negative mutant of 
IRF-3 (IRF-358-427/IRF-3D) that lacks a functional DNA-binding domain (also kindly provided 
by T. Fujita, Kyoto, Japan) were co-transfected into 293 cells. Cells were infected as 
described above and luciferase activity was measured 10 hours post infection. Indeed, the 
presence of the dominant negative IRF-3 led to decreased luciferase activity in cells infected 
with BRSV D1/2, BRSV h1/2, HRSV, or wt BRSV, confirming the strict requirement of 
functional IRF-3 for IFN-b  expression in 293 cells (Fig. 27B).  
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Fig. 27: Virus-induced activation of the IFN-b promoter. (A) 293 cells were transfected with a luciferase 
construct driven by the IFN-b promoter/enhancer (p125Luc). 24 hrs post transfection cells were mock-infected 
or infected with BRSV D1/2 at an MOI of 0.3. Cells were harvested at indicated time points followed by a 
luciferase assay. The mean value of mock-infected cells was set to 1; values obtained for BRSV D1/2 infected 
cells in two independent experiments are shown as fold induction. (B) 293 cells were transfected with p125Luc. 
When indicated, cells were co-transfected with an expression plasmid coding for a dominant negative mutant of 
IRF-3 (IRF-3D). 24 hrs post transfection cells were infected with the indicated viruses at an MOI of 0.25. Cells 
were harvested 10 hrs post infection followed by a luciferase assay. Results represent the mean value of three 
independent experiments with error bars indicating standard deviation. 
 
 
Transfection of the dsRNA analog poly I/C into cells was shown to trigger the induction of 
IFN-b (49). To investigate whether wild-type BRSV can inhibit this dsRNA-stimulated 
induction, 293 cells were mock- infected or infected with BRSV wt at an MOI of 0.25. 
Fourteen hours post infection, cells were transfected with p125Luc followed by a second 
transfection with increasing amounts of poly I/C at 24 hrs post infection. 38 hrs post infection, 
cells were harvested and luciferase activity measured. Indeed, whereas increasing poly I/C 
concentrations resulted in increased luciferase activity in mock- infected cells, luciferase 
activity levels remained low in wild-type BRSV infected cells (Fig. 28A) demonstrating that 
BRSV is able to inhibit the induction of IFN even in the presence of an additional, dsRNA-
based trigger. In addition, aliquots of the cell lysates were subjected to SDS-PAGE to assay 
for upregulation of ISGs, here IRF-9. As expected, the amount of p48 (IRF-9) increased only 
in mock- infected cells treated with poly I/C but not in BRSV wt infected cells (Fig. 28B), and 
replication of BRSV was not impaired as shown by unchanging amounts of the RSV N, P, 
and M proteins in poly I/C treated cells (Fig. 28B). 
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Fig. 28: BRSV wt inhibits IFN induction triggered by poly I/C. (A) 293 cells were mock-infected or infected 
with BRSV wt at an MOI of 0.25. Cells were then subsequently transfected with p125Luc and increasing 
amounts of poly I/C. Cells were harvested 38 hrs post infection followed by a luciferase assay. Relative light 
units measured are given in fold induction and represent the mean value of three independent experiments. (B) 
Western blot analysis of cell lysates obtained in (A). Blots were probed with antibodies recognizing the ISG 
IRF-9 (p48) and PCNA as loading control. BRSV N, P, and M proteins were detected with an a-RSV serum. 
 
 
BRSV wt prevents activation of IRF-3 
 
Activation of IRF-3 is a prerequisite for the induction of the IFN-b gene. In non- infected 
cells, IRF-3 is present in its inactive form and restricted to the cytoplasm. Virus infection but 
not IFN treatment induces phosphorylation of IRF-3 on specific serine residues, thereby 
allowing it to translocate into the nucleus, associate with its co-factor CBP/p300 and 
subsequently activate the transcription of genes encoding type I IFNs. To investigate whether 
IRF-3 phosphorylation is impaired in the presence of the BRSV NS proteins, 293 cells were 
mock-infected or infected with wt BRSV, BRSV D1/2, BRSV h1/2 or HRSV and harvested 8 
hours post infection. Nuclei were prepared as described in Materials and Methods (2-14), and 
equal amounts of nuclear extract were subjected to SDS PAGE followed by Western blotting 
and subsequent probing of the membrane with an antibody recognizing IRF-3. Virus- induced 
phosphorylation of IRF-3 was shown to result in a concomitant change in mobility in SDS 
gels (106). In nuclear extracts of cells infected with BRSV D1/2, BRSV h1/2, or HRSV a 
slower migrating band was detected by the IRF-3 antibody, indicating the presence of  
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substantial amounts of phosphorylated IRF-3 in infected 293 cells (Fig. 29). However, in 
BRSV wt infected cells no such band was present indicating that in the context of a viral 
infection, the nonstructural proteins NS1 and NS2 are able to inhibit phosphorylation of IRF-3 
and subsequent nuclear translocation by an as of yet unknown mechanism, thereby preventing 
IFN induction and the subsequent establishment of the antiviral state. 
 
 
 
Fig. 29: Phosphorylation of IRF-3 upon viral infection. 293 cells were mock-infected or infected with the 
indicated viruses at an MOI of 0.25. Ten hours post infection cells were harvested. Nuclear extracts were 
prepared as described in 2-14 and equal amounts of cell extract were subjected to SDS-PAGE. 
Nonphosphorylated and phosphorylated forms of IRF-3 were both detected with a-IRF-3 antibody.  
 
 
To confirm the absence of activated IRF-3 in BRSV wt infected cells, I took advantage of  a 
reporter construct containing the IRF-3 binding sequence from the IFN-b  promoter upstream 
of the luciferase gene (kindly provided by T. Fujita, Kyoto, Japan). 293 cells were transfected 
with the reporter construct and infected 8 hrs later with BRSV wt, BRSV D1/2 or BRSV h1/2 
at an MOI of 0.2. 14 hrs post infection cells were harvested and luciferase activity was 
measured. As expected, infection with BRSV D1/2 and BRSV h1/2 resulted in a more than 
30-fold increase in luciferase activity, whereas only a small, 3- fold increase was detected in 
wt BRSV infected cells (Fig. 30) demonstrating that the virus-specific activation 
(phosphorylation) of IRF-3 is indeed blocked in the presence of the two BRSV NS proteins.  
To further investigate whether the two other key transcription factors involved in the 
induction of the IFN-b gene, NF-kB and AP-1 (ATF-2/c-Jun) are also not active in BRSV wt 
infected cells, 293 cells were transfected with plasmids harboring NF-kB or AP-1 binding 
sequences that control expression of the downstream luciferase gene (Stratagene, see also 1-
5). Again, 293 cells were transfected with each reporter construct and mock- infected or 
infected with BRSV wt, BRSV D1/2 or BRSV h1/2 at an MOI of 0.2.  Interestingly, infection 
with BRSV wt activated the AP-1 and NF-kB reporter 3-fold and 10-fold, respectively, 
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similar to luciferase activity levels observed in BRSV D1/2 or BRSV h1/2 infected cells (Fig. 
30). These data suggest that BRSV wt selectively blocks virus- induced phosphorylation of 
IRF-3 to achieve inhibition of IFN induction. 
 
 
Fig. 30: BRSV wt selectively blocks activation of IRF-3. 293 cells were transfected with luciferase constructs 
under the control of promoters containing either IRF-3, AP-1 or NF-kB binding sequences. 8 hrs p.t. cells were 
infected with the indicated viruses at an MOI of 0.2. 14 hrs p.i. cells were harvested, followed by a luciferase 
assay. The mean value of mock-infected cells was set to 1. Results show the mean value of two independent 
experiments. 
 
 
Both NS proteins are required for inhibition of IFN induction 
 
To investigate which NS protein is required to block IFN induction, 293 cells previously 
transfected with the IFN-b  reporter construct were infected with the single NS deletion 
mutants BRSV D1 and BRSV D2, the double deletion mutant BRSV D1/2, and the wild-type 
BRSV, and reporter gene activity was measured 14 hrs post infection. As expected, cells 
infected with BRSV wt did not yield increased IFN-b  promoter activity compared to mock-
infected cells. However, in BRSV D1 and BRSV D2 infected 293 cells an approximately 15-
fold induction of luciferase activity was measured (Fig. 31). In the same experiment, a 17-fold 
induction was found in cells infected with the double deletion mutant BRSV D1/2. These data 
indicate that both NS proteins of BRSV are required not only for IFN antagonist activity but 
also for inhibition of IFN-b  promoter induction. 
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Fig. 31: BRSV NS deletion mutants induce IFN-b promoter. 293 cells were transfected with p125Luc, and 8 
hrs post transfection cells were infected with the indicated viruses at an MOI of 0.2. 14 hrs post infection cells 
were harvested and a luciferase assay was performed. Results represent the mean value of three independent 
experiments with error bars indicating standard deviation. 
 
 
HRSV and BRSV NS proteins cooperate in blocking IFN induction 
 
Since only the BRSV NS proteins are able to inhibit induction of IFN, I was interested to see 
how the chimeric BRSVs carrying one BRSV and one HRSV NS gene (BRSV h1 and BRSV 
h2, respectively) would cope with the cellular IFN system. Therefore, MDBK cells were 
infected with wt BRSV, BRSV h1, BRSV h2, and BRSV h1/2 and upregulation of STAT2 
was monitored 24 hrs post infection.  
Surprisingly, infection of MDBK cells with BRSV h1 or BRSV h2 did not lead to 
increased STAT2 levels (Fig. 32A) indicating that both combinations of HRSV and BRSV 
NS proteins are functional in blocking the upregulation of STAT2 production. In addition, 
induction of the IFN-b  gene promoter was inhibited in BRSV h1 or BRSV h2 infected 293 
cells whereas for BRSV h1/2 or the parental HRSV Long a 16- and 18-fold induction, 
respectively, was found (Fig. 32B). To confirm this finding, the presence of a slower 
migrating band representing phosphorylated IRF-3 was monitored in infected 293 cells. As 
expected, phosphorylated IRF-3 was not found in nuclear extracts of BRSV h1 or BRSV h2-
infected cells (Fig. 32B) suggesting that, intriguingly, both combinations of BRSV and HRSV 
NS proteins are successful in preventing the activation of IRF-3. The chimeric BRSV h1 and 
BRSV h2 will be a useful tool for the identification of sequences or domains of the BRSV NS 
proteins responsible for the block in the induction of the IFN-b  promoter and may help 
explain how either BRSV NS protein succeeds in forcing the respective other HRSV NS 
protein to cooperate in blocking IFN induction. 
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Fig. 32: BRSV h1 and BRSV h2 block IFN induction. (A) MDBK cells were infected with the indicated 
viruses at an MOI of 0.2. 24 hrs post infection cells were harvested and equal amounts of cell extract were 
subjected to SDS-PAGE followed by Western blot and detection of STAT2 and PCNA as loading control. (B) 
293 cells were transfected with the IFN-b reporter construct p125Luc. Eight hours post infection cells were 
infected with the indicated viruses at an MOI of 0.2. Cells were harvested 14 hrs post infection followed by 
luciferase assays. Results represent the mean value of three independent experiments with error bars indicating 
standard deviation. (C) 293 cells were infected with the indicated viruses at an MOI of 0.25. Nuclear extracts 
were prepared 8 hrs post infection and equal amounts of extract were subjected to SDS-PAGE. The membrane 
was probed with an antibody recognizing IRF-3. 
 
 
 
PVM NS proteins cannot prevent induction of IFN 
 
To test whether the PVM NS proteins, in contrast to the HRSV NS proteins, are able to 
prevent IFN induction, MDBK cells were mock- infected or infected with BRSV wt and 
BRSV m1/2 at an MOI of 0.2, and STAT2 levels were determined 24 and 48 hrs post 
infection. Similar to BRSV h1/2, STAT2 expression was upregulated in BRSV m1/2 infected 
cells indicating that also the PVM NS proteins do not possess the capacity to inhibit ISG 
upregulation (Fig. 33A).  
These findings were also confirmed in reporter gene assays. 293 cells were transfected 
with p125Luc and subsequently mock- infected or infected with BRSV wt or BRSV m1/2 at 
an MOI of 0.2. 10 hours post infection cells were harvested and luciferase activity was 
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measured. Whereas infection of cells with wt BRSV resulted in only a 2.5-fold increase in 
luciferase activity, infection of cells with BRSV m1/2 led to a 17-fold induction similar to 
induction levels found in BRSV D1/2-infected cells (Fig. 33B) demonstrating that the PVM 
NS proteins are – in a BRSV background – not able to inhibit the induction of the IFN-b  gene 
promoter in cells of bovine or human origin. 
 
 
 
Fig. 33: Antiviral state is established in BRSV m1/2 infected cells.  (A) MDBK cells were infected with 
BRSV wt and BRSV m1/2 at an MOI of 0.2, and cell were harvested at the indicated time points. Equal amounts 
of cell extract were subjected to SDS-PAGE and membranes were probed with antibodies recognizing STAT2 
and PCNA. (B) 293 cells were transfected with p125Luc, followed by infection with BRSV wt or BRSV m1/2 at 
an MOI of 0.2. 10 hrs post infection cells were harvested and luciferase assays performed. Results represent the 
mean value of three independent experiments with error bars indicating standard deviation. 
 
 
 
It was then of interest to see whether the PVM NS proteins are able to inhibit IFN induction in 
murine cells. Two different murine cell lines, L929 and NIH3T3, were infected with various 
recombinant BRSVs, and upregulation of STAT2 was monitored at different time points by 
Western blot. In both cell lines, infection with BRSV m1/2 and BRSV D1/2 yielded increased 
STAT2 levels (Fig. 34) indicating that also in murine cells, the PVM NS proteins are not able 
to block upregulation of ISGs. However, unexpectedly, wt BRSV was not able to prevent the 
upregulation of STAT2 levels in murine cells suggesting that the capacity of the BRSV NS 
proteins to inhibit IFN induction is host cell dependent (Fig. 34) and might involve cellular 
factors not highly conserved between different species.  
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Fig. 34: ISG upregulation in infected murine cells. L929 and NIH3T3 cells were infected with BRSV wt, 
BRSV m1/2, or BRSV D1/2 at an MOI of 0.2. As control for ISG upregulation, mock-infected cells were treated 
with 2000 U/ml of a recombinant IFN-a immediately after seeding. Cells were harvested at indicated time points 
and cell extracts were subjected to SDS-PAGE followed by Western blotting using a murine-specific STAT2 
antibody and an antibody recognizing PCNA as loading control. 
 
 
 
 
 
4 EXCURSUS: CELLULAR LOCALIZATION OF 
PNEUMOVIRUS NS PROTEINS 
 
 
Pneumovirus NS proteins show nuclear localization 
 
The generation of BRSVs expressing various tagged pneumovirus NS genes enabled us to 
study the subcellular localization of these proteins. Vero cells were infected at an MOI of 0.1 
with both BRSV ha and BRSV fl, and seeded into 6-well plates as described in Materials and 
Methods (2-10). Two days post infection cells were fixed, permeabilized and stained with 
antibodies recognizing the respective sequence tag (HA or FLAG). In addition, cells were 
stained with an antibody recognizing the nucleoprotein N. To our surprise, whereas the 
nucleoprotein was exclusively found in the cytoplasm, both NS proteins were present in the 
nucleus as well as in the cytoplasm, an astonishing finding considering the entirely 
cytoplasmic replication of BRSV (Fig. 35A). Furthermore, both proteins colocalize with 
“inclusion bodies” consisting of N, P, and M protein. In a similar experiment, to confirm the 
localization of the NS proteins in the nucleus, the nuclei of Vero cells were additionally 
stained with propidium iodide. Again, both NS proteins were found in the nucleus and the 
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cytosol of infected cells (Fig. 35B). In addition, in dividing cells, both NS proteins were 
distributed throughout the cytoplasm but were not found to colocalize with propidium iodide-
stained chromosomes (Fig. 35B).  
 
 
 
 
Fig. 35: B RSV NS proteins are localized in the nucleus. Vero cells were infected at an MOI of 0.1 with BRSV 
ha or BRSV fl, and fixed in 3% paraformaldehyde 2 days post infection. Cells were then stained with antibodies 
recognizing the respective sequence tag (Y-11 for NS1ha; M2 for NS2fl). (A) Cells were additionally stained 
with an antibody recognizing BRSV N protein (79N; kindly provided by J.A. Melero, Spain). (B) Nuclei were 
stained with propidium iodide. 
 
 
To find out whether nuclear localization is a peculiarity of the BRSV NS proteins, the 
immunofluorescent studies were extended to the HRSV and PVM NS proteins. For that 
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purpose, Vero cells were infected with various chimeric BRSVs, and two days post infection 
cells were fixed as described in 2-10. Intriguingly, despite the lack of any sequence homology 
with BRSV NS proteins, the PVM NS proteins were also found in the cytosol and the nuclei 
of infected cells, as shown in Fig. 36. Furthermore, both PVM NS proteins appeared to reach 
the nucleus independently of each other, since no difference in their location was observed 
using either BRSV m1, BRSV m2, or BRSV m1/2.  
 
Fig. 36: Cellular localization of PVM NS proteins. Vero cells were infected with indicated viruses at an MOI 
of 0.1 and fixed 2 days post infection. PVM NS1 was detected with Y-11 recognizing the HA-tag. PVM NS2 
was detected using the M2 antibody recognizing the FLAG epitope. Cells were also stained with an antibody 
recognizing BRSV N protein (79N; kindly provided by J. A. Melero, Spain). 
 
 
Detection of the HRSV NS proteins proved to be more difficult. The peptide serum raised 
against HRSV NS1, a-NS1, gave only very weak signals whereas a-IC/C gave rise to high 
background stainings. In addition, a-IC/C is known to cross-react with the NS2 protein of 
HRSV and BRSV. Therefore, in cells infected with BRSV h1 or BRSV h1/2, there is no 
distinction possible between the HRSV NS1 and the BRSV NS2 protein (in the case of BRSV 
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h1), or between both HRSV NS proteins (in the case of BRSV h1/2) when a-IC/C is used. 
Nevertheless, in Vero cells infected with BRSV h1 or BRSV h1/2, staining of nuclei was 
found when antibody a-NS1, recognizing solely the HRSV NS1 protein, was used (Fig. 37). 
Furthermore, in BRSV h2- infected cells, detection of HRSV NS2 with antibody a-IC/C gave 
a slight nuclear staining demonstrating that also the HRSV NS proteins are localized in both 
cytosol and nucleus. From these studies we conclude that the surprising nuclear localization 
of the nonstructural proteins is conserved between all pneumovirus NS proteins and may have 
a vital function in viral replication and virus-host interaction. Interestingly, all NS proteins 
were also present in cytosolic “inclusion bodies” thought to represent conglomerates of N, P, 
and M protein. 
 
 
 
Fig. 37: Cellular localization of HRSV NS proteins. Vero cells were infected with the indicated viruses at an 
MOI of 0.1. Two days post infection cells were fixed and NS proteins detected using either a-NS1 (recognizing 
HRSV NS1) or a-IC/C (recognizing HRSV NS1, HRSV NS2 and BRSV NS2). In addition, cells were stained 
with an antibody recognizing BRSV N protein (79N; all antibodies were kindly provided by J.A. Melero). 
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NS proteins reach nucleus independent of other pneumovirus proteins 
 
To investigate whether the pneumovirus NS proteins are also present in the nucleus when 
expressed independently of the BRSV background, we infected Vero cells with the 
recombinant Rabies Viruses expressing single NS proteins. Three days post infection (in the 
case of VB bNS1 two days post infection), cells were fixed in 3% paraformaldehyde and 
stained for the respective NS protein. In addition, cells were stained with CentocorÒ, a FITC-
conjugated antibody recognizing RV N protein, to demonstrate RV-infection.  
 
 
 
 
 
 
Fig. 38: Localization of pneumovirus NS proteins expressed from rRVs. Vero cells were infected with 
indicated viruses at an MOI of 0.1, and cells were fixed 2 (in the case of VB bNS1) or 3 days post infection (VB 
mNS1, VB hNS1, VB mNS2). BRSV and PVM NS1 were detected using an antibody recognizing the HA-tag 
(Y-11); HRSV NS1 was detected with a-IC/C (kindly provided by J.A. Melero, Spain), PVM NS2 was detected 
with an a-FLAG antibody (M2). Centocor was used to stain RV-infected cells. 
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Whereas for the HRSV and BRSV NS2 protein no immunofluorescent signal above 
background levels was detectable in several independent experiments, all three pneumovirus 
NS1 proteins and the NS2 protein of PVM showed the expected cellular localization (Fig. 38) 
suggesting that at least these NS proteins reach the nuclear compartment without support of 
other pneumoviral proteins.   
 
 
Pneumovirus NS proteins are retained in the nucleus 
 
Interestingly, neither NS protein contains a classical nuclear localization signal (NLS; stretch 
of basic amino acids that mediates binding to import receptors such as importin b  (50)) that 
could account for its nuclear localization. However, all NS proteins are below the limit of 40 
to 60 kDa allowing passive diffusion through the nuclear pore. It was therefore appealing to 
inquire whether the NS proteins are retained in the nuclear compartment by binding to cellular 
factors after their entry into the nucleus.  
 
 
 
 
Fig. 39: BRSV NS proteins and PVM NS1 are retained in the nucleus. Vero cells were infected with BRSV 
ha, BRSV fl, and BRSV m1/2, at an MOI of 0.1. Two days post infection, cells were either fixed with 3% 
paraformaldehyde or treated with digitonin and Triton X-100 prior to fixation with paraformaldehyde. Cells were 
then permeabilized with 0.5% Triton X-100. NS1 proteins were detected with an antibody recognizing the HA-
tag (Y-11), BRSV NS2 was detected with M2 antibody recognizing the FLAG-tag. As internal control, Vero 
cells were transfected with an expression plasmid for EGFP. Two days post infection, cells were treated as 
described above. In addition, cells were stained with an antibody recognizing the nuclear RNA helicase p68 (red 
staining). 
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To wash out nonanchored proteins, Vero cells infected with BRSV ha, BRSV fl or BRSV 
m1/2 were treated with digitonin (40 mg/ml in PBS) for 3 min on ice, then washed once with 
cold PBS. Afterwards, cells were incubated with 0.025% Triton X-100 for 5 min on ice before 
fixation in 3% paraformaldehyde and permeabilization with 0.5% Triton X-100.  As control, 
infected cells were only fixed in 3% paraformaldehyde. To validate this assay, cells were 
transfected with a reporter construct expressing the green fluorescent protein (GFP) and 
treated as described above. Normally, GFP is found evenly distributed throughout the cell 
including the nuclear compartment and nucleoli. Treatment with digitonin and Triton X-100, 
however, eliminated the fluorescence of GFP but not the staining for p68, a nuclear RNA 
helicase (Fig. 39). Similar to the nuclear protein p68, the BRSV NS proteins and PVM NS1 
are localized in the nucleus in a speckle- like pattern in both untreated and digitonin/Triton X-
100-treated cells (Fig. 39). From that we conclude that the NS proteins are retained in the 
nucleus upon entry, probably by interacting with nuclear factors, suggesting a distinct 
function for the nuclear NS proteins during viral replication. 
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DISCUSSION 
 
Pneumovirus NS proteins are IFN antagonists 
 
A peculiarity of pneumoviruses is the presence of two nonstructural protein genes at the very 
3’ end of the genome. Deletion of one or both nonstructural genes leads to attenuation of the 
respective pneumovirus in vitro and in vivo indicating that both proteins contribute to optimal 
viral replication but are not essential. However, the precise role(s) of the nonstructural 
proteins in the viral life cycle remain to be defined. Employing the technique of recovery of 
negative-strand RNA viruses from cDNA, several NS deletion mutants of BRSV were 
generated in our laboratory. Although only slightly attenuated in IFN-negative Vero cells not 
able to produce IFN, growth of these deletion mutants was severely impeded in IFN 
producing bovine MDBK cells which are fully permissive for the wild-type virus (80). 
Assuming that this severe attenuation was due to missing virus-host interactions, type I 
interferons (IFN-a/b) were subsequently identified as the critical host cell factors produced by 
infected MDBK cells (80). Intriguingly, however, growth kinetics and IFN sensitivity of 
deletion mutants lacking either NS1 or NS2, or both NS genes, were very similar in all cell 
lines examined suggesting that, quite unexpectedly, both NS proteins are apparently necessary 
to accomplish IFN antagonistic activity whereas each protein on its own does not possess any 
activity. To our knowledge, this would be the first example of two virus proteins obligatorily 
cooperating to antagonize IFN.  
 To obtain evidence that both nonstructural proteins are required and sufficient to 
interfere with the IFN-induced antiviral state, recombinant RVs expressing individual NS 
proteins were generated. The location of the NS genes at the most upstream position of the 
RSV genome (Fig. 2) should result in a high and similar level of expression in BRSV-infected 
cells. Accordingly, to simulate the conditions in BRSV-infected cells, coinfections with rRV 
vectors harboring individual NS genes were done at the same MOI for both recombinants. 
Comparable amounts of NS1 and NS2 protein, respectively, should be expressed in cells 
infected with the single recombinants and in cells coinfected with both recombinants. 
However, only in coinfected cells was a significantly enhanced resistance of the RV vector to 
IFN stimulation observed. Whereas standard RV titers dropped by 3 log units in MDBK cells 
when only 50 IU of recombinant IFN were applied, complete protection was observed in 
coinfected cells treated with IFN doses of up to 150 IU demonstrating that the two BRSV NS 
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proteins are indeed able to confer resistance against IFN-mediated antiviral responses (Fig. 
10). Furthermore, the results confirm that the presence of both proteins is required for 
exerting their IFN antagonist activity. Since the NS proteins are not only effective in a BRSV 
background but are also able to protect a heterologous virus from INF-induced responses, 
NS1 and NS2 do not require additional viral functions provided by BRSV for their protective 
activity. 
 
Since coinfections are prone to some variability and do not result in complete coinfection of 
all infected cells, we suspected that a more regulated coexpression of NS proteins might bring 
about a greater protective capacity. Therefore, a recombinant RV was generated that 
expresses both NS protein of BRSV. As expected, this virus was significantly more IFN 
resistant than standard RV even when 500 IU of recombinant IFN were applied (Fig. 16). 
Somewhat surprisingly, the introduction of two additional genes into the RV genome did not 
attenuate viral replication significantly when compared to wild-type RV. Similarly, 
expression of the influenza NS1 protein also showed beneficial effects towards the IFN 
resistance of RV vectors without hampering its replication capacity (B. Bossert, unpublished 
results). The generation of  replication-competent viral vectors with improved IFN resistance 
capacities will provide a useful tool to study the in vivo function of a given IFN antagonist 
and to identify possible novel IFN antagonists. 
 
Previous studies from Young et al. showed that HRSV is able to replicate in human cells that 
produce and respond to IFN, suggesting that HRSV must have some effective means to 
replicate in the face of the cellular antiviral response (108). Since the nonstructural proteins of 
HRSV and BRSV are highly similar in sequence, with 69 and 84% amino acid identity for the 
NS1 and NS2 proteins, respectively, we entertained the idea that the HRSV NS proteins might 
also function as IFN antagonists. Using rRVs expressing individual HRSV NS proteins, I 
could demonstrate that only in cells coinfected with both recombinants, IFN resistance of the 
RV vector towards exogenous IFN was enhanced (Fig. 14). Moreover, their capacity to 
mediate virus escape from IFN-a/b-induced antiviral mechanisms was comparable to that of 
the BRSV NS proteins. As previously shown for the BRSV NS proteins, the presence of both 
HRSV NS proteins is required for their IFN antagonist activity. Identical experiments were 
also performed with the nonstructural proteins of the only very distantly related Pneumovirus 
of Mice (PVM). Recombinant RVs were generated expressing single PVM NS proteins and 
IFN challenge experiments in MDBK cells were carried out. Although the PVM NS proteins 
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show only low sequence homology to their human and bovine RSV counterparts (Fig. 5), they 
still have the capacity to render the RV vector IFN resistent, albeit to a somewhat lesser extent 
than the RSV NS proteins (Fig. 14). Again, the presence of both NS1 and NS2 is required for 
the observed IFN antagonist function.  
These data clearly show that pneumoviruses share a common IFN resistance mechanism 
that requires the presence of both nonstructural proteins and that can be transferred to an 
unrelated rhabdovirus. Preliminary studies indicate that Rabies virus is insensitive to MxA  
(R. Müller-Waldeck, unpublished results). Thus, I assume that the NS proteins block the 
action of specific IFN-induced antiviral gene products other than MxA to accomplish 
resistance to IFN. The high sequence similarity of HRSV and BRSV NS proteins and, 
moreover, their functional cooperativity (Fig. 15) suggest that BRSV and HRSV interfere 
with the same IFN-induced antiviral mechanisms and that they target similar, if not the same, 
antiviral gene products. In contrast, the highly dissimilar NS proteins of PVM were not able 
to cooperate with their bovine counterparts. Yet, functionally, the presence of both proteins is 
required. It is tempting to speculate that the PVM proteins have evolved to better suit their 
targets in a murine IFN system, thus conserving the mechanism that renders pneumoviruses 
IFN resistant.  
 
 
Involvement of pneumovirus NS proteins in the determination of host range  
 
Although closely related, bovine and human RSVs display a highly restricted host range in 
vivo. One reason might be restricted entry into host target cells due to differences in the viral 
surface glycoproteins and in their cellular receptor. In vitro, however, BRSV and HRSV are 
able to enter a wide variety of cells of different hosts indicating that other virally encoded 
factors may also play a pivotal role in determining host range. Indeed, Buchholz et al. 
reported that a chimeric BRSV carrying the HRSV glycoproteins instead of their BRSV 
counterparts was somewhat more competent than BRSV for replication in chimpanzees but 
remained highly restricted compared to HRSV (9). The authors concluded that the F and G 
proteins contribute to the host range restriction of BRSV but are not the major determinants.  
In this study we demonstrate that the NS proteins of BRSV and HRSV represent 
important determinants of viral host range in that they display a differential ability to 
counteract innate responses in cells of different hosts. In Vero cells unable to produce IFN, 
viral replication of wild-type BRSV and the various chimeric BRSV h1, BRSV h2, and BRSV 
h1/2 was indistinguishable (Fig. 18B). This is notable, as the HRSV NS1 protein was shown 
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to associate with the viral matrix protein M (33) and was reported to be a potent inhibitor of 
viral transcription and RNA replication in a HRSV minigenome system (3). The virtually 
identical growth in Vero cells suggests that these interactions and functions were not largely 
affected in the chimeric virus and that the HRSV NS proteins are able to accurately fulfill the 
function(s) of their bovine counterparts during viral replication. When growth properties of 
different chimeric BRSVs were assessed in cells harboring an intact IFN system, differences 
in the ability to counteract host specific IFN-induced antiviral cell responses became obvious 
and even more evident in IFN-treated cells. In cells of bovine origin, BRSV was perfectly 
protected even against high doses of exogenous IFN-a whereas BRSV h1/2 was severely 
attenuated (Fig. 19C) and highly sensitive towards IFN-a (Fig. 20B). In human cells, both 
viruses displayed similar growth characteristics (Fig. 19B), but BRSV h1/2 was more resistant 
than BRSV wt to antiviral responses triggered by exogenous IFN (Fig. 20C). Although IFN 
resistance of BRSV h1/2 was greater than wt BRSV, this did not result in higher titers in the 
absence of exogenous IFN. I therefore assume that, most probably, IFN induction and the 
activation of antiviral mechanisms are not sufficient to completely overcome the weaker IFN 
resistance of wt BRSV. In contrast, infected MDBK and Klu cells are likely to be strong 
inducers of IFN so that differences in IFN escape are immediately apparent.  
In the case of the recombinant BRSVs expressing one or both PVM NS proteins, 
replication was attenuated in Vero cells not able to produce IFN, and resembled replication 
levels obtained with the double deletion mutant BRSV D1/2 (Fig. 22B). This suggests that the 
PVM NS proteins are, unlike their human counterparts, not able to functionally replace the 
BRSV NS proteins during the viral life cycle. How the NS proteins contribute in detail to 
viral replication is not yet known.  Atreya et al. reported an inhibitory effect of NS1 on 
transcription and RNA replication in a HRSV minigenome system (3). However, deletion of 
NS1 from the HRSV or BRSV genome did not lead to enhanced replication. In contrast, NS 
single or double deletion mutants were attenuated even in IFN negative cells suggesting a 
supportive rather than an inhibitory function for the NS proteins in viral replication (8,80). 
Although the PVM NS proteins cannot replace their bovine counterparts in their 
replicative function(s), the recombinant virus expressing both PVM NS proteins, BRSV m1/2, 
showed improved growth characteristics compared to BRSV D1/2 in IFN-producing cells 
(Fig. 23) and was almost as IFN resistant as the wt BRSV (Fig. 22C) indicating that the PVM 
NS proteins confer IFN resistance independent of their viral context.  
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The contribution of pneumovirus NS proteins to the permissivity of hosts to RSV infection is  
supported by the study of Hanada et al. reporting that the markedly restricted growth of 
HRSV in mouse embryo cells could be overcome by adding anti-mouse IFN serum to the 
medium (43). As a result, HRSV yields were enhanced and the infection spread in the entire 
monolayer. Apparently, entry into mouse cells was not the limiting step but rather the 
inability of the HRSV NS proteins to efficiently counteract murine IFN responses. However, 
infection of murine cells with BRSV is even more inefficient than with HRSV, and mice 
infected with BRSV do not develop any symptoms. Therefore, in vivo infection studies with 
BRSV have to be carried out in, preferably gnotobiotic, calves. The development of “mouse-
improved” recombinant BRSVs expressing e.g. the HRSV glycoproteins for better entry into 
murine cells and the NS proteins of PVM to inhibit murine IFN responses might allow the 
study of BRSV pathogenesis in a “small animal” model and might help to gain insight into the 
difficult virus – host immune system interactions encountered during pneumovirus infections. 
 
Adaptation of viral proteins to the cellular environment of their natural host may in fact play a 
critical role in establishing an infection. The V protein of Simian Virus 5 (SV5), for example, 
is very effective in blocking the activation of IFN-responsive genes in primate cells but not in 
murine cells (28). A single amino acid substitution, however, renders the V protein fully 
functional to block IFN signaling in murine cells (107). Further studies with chimeric RSV 
recombinants will reveal whether the observed species specificity in IFN escape can also be 
attributed to the PVM NS proteins. Moreover, it will be interesting to see whether the species 
specificity can be ascribed to one of the two NS proteins and which sequences are involved. 
In addition, mutations in the NS proteins may be identified that only partially knock out the 
IFN-antagonist activity without compromising NS protein function necessary for optimal viral 
replication. This would lead to the generation of replication competent RSVs that display a 
reduced capability of antagonizing IFN in a given host. 
  
The ability to adjust IFN resistance will also have important implications for the development 
of an efficacious live attenuated RSV vaccine. The first vaccine evaluated in infants and 
children in the mid-1960s consisted of formalin- inactivated and concentrated RSV. However, 
the vaccine was not able to induce a protective immune response. Moreover, during 
subsequent natural infections, the frequency and severity of RSV disease was increased 
(54,55). In contrast, a live attenuated vaccine administered intranasally may have the 
advantage of mimicking natural infection, which has never been shown to prime for enhanced 
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disease (96), and may be able to replicate in very young infants despite the presence of 
maternal antibodies (104). For these reasons, a series of attenuated, immunogenic cold-
passaged, temperature-sensitive RSV mutants were produced and clinically evaluated. The 
most attenuated vaccine virus, cpts248/404, was immunogenic and protective against a second 
vaccine dose. However, it induced mild nasal congestion indicating the need for additional 
attenuation (104). The ability to recover infectious, recombinant RSV from cDNA has greatly 
facilitated the characterization and further development of live-attenuated viruses (20) and 
might provide the tool for further attenuation (17). The deletion of nonessential genes such as 
one or both nonstructural genes, however, resulted in attenuated, highly IFN sensitive virus 
with compromised pathogenicity (8,52,87,88,101). In addition, virus replication was also 
affected resulting in reduced production of antigen and poor immunogenicity. The challenge 
in the development of a live attenuated vaccine will be the elimination of residual virulence 
without compromising immunogenicity. BRSV and HRSV vaccines that possess intermediate 
ability to escape from the innate bovine or human immune response but are nevertheless able 
to keep their replicative capacity are a very promising approach. 
 
 
BRSV NS proteins are required for inhibition of IFN-b induction 
 
Recently, the accessory V and C proteins of certain members of the Paramyxovirinae 
subfamily have been shown to function as antagonists of the interferon system by blocking 
signaling pathways induced by IFN (35). In contrast, HRSV (a member of the Pneumovirinae 
subfamily) failed to block IFN signaling but was able to replicate in cells pretreated with IFN 
indicating that HRSV must have some alternative mechanism for circumventing the IFN 
response (108). Subsequently, we were able to demonstrate that the two NS proteins, present 
only in the Pneumovirinae subfamily, are able to confer resistance towards IFN-induced 
responses. These results suggest that whereas interference with IFN signaling is a common 
strategy among the Paramyxovirinae, Pneumovirinae members do not inhibit signaling but 
have developed as of yet unknown strategies to block the IFN-induced antiviral response (Fig. 
40). 
Here, we describe an additional, novel function for the NS proteins of BRSV, namely 
their ability to block the early stages of the virus-activated cellular IFN pathway by interfering 
with the activation of IRF-3 (Fig. 40). As a result, induction of IFN-b  and the subsequent 
establishment of the antiviral state are prevented or at least very much delayed.  
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Fig. 40: Pneumovirus NS proteins interfere with the cellular IFN system. Whereas HRSV, BRSV and PVM 
NS proteins are able to confer resistance to IFN, only the NS proteins of BRSV are in addition able to inhibit the 
activation of the IFN-b promoter by preventing the phosphorylation and subsequent activation of IRF-3.  
 
 
The first indication of an impaired cellular antiviral state in BRSV-infected cells was 
observed in IFN-competent MDBK and HEp-2 cells. Infection with the double deletion 
mutant BRSV D1/2 resulted in increased expression of interferon stimulated genes (ISGs) 
such as PKR, STAT2 and IRF-9 (25), demonstrating the successful establishment of the 
antiviral state in BRSV D1/2- infected cells (Fig. 24A/B). However, to our surprise, in wild-
type BRSV-infected cells, this upregulation was absent, suggesting that in the presence of the 
two NS proteins upregulation of ISGs was impaired. Unexpectedly, infection with a chimeric 
BRSV expressing both HRSV NS genes, BRSV h1/2, resulted in enhanced PKR, STAT2 and 
IRF-9 levels comparable to levels found in BRSV D1/2- infected cells. Infection with the 
parental HRSV Long gave similar results (Fig. 24C) indicating that the HRSV NS proteins 
are not able to block the expression of ISGs upon virus infection in vitro. This finding is 
supported by other in vitro studies that report increased expression of ISGs such as MHC 
class I or inducible NO synthetase after infection with HRSV (36,90). Although the closely 
related BRSV and HRSV NS proteins share similar functions in mediating resistance towards 
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IFN-induced cellular antiviral mechanisms and are even able to cooperate for this particular 
function, they apparently differ in their ability to block the establishment of an antiviral state. 
However, since the ability of HRSV to induce IFN and the IFN-mediated cellular response in 
vivo is still a matter of debate, it remains to be investigated whether the inability of HRSV in 
preventing the upregulation of ISGs is a particular feature of the HRSV strain Long and 
whether other strains or clinical isolates are more inhibitory. The very distant PVM NS 
proteins were also found unable to prevent induction of IFN-b when expressed in a BRSV 
background (Fig. 33). However, no data are at present available whether infection of murine 
cells with the parental PVM induces IFN production or not.  
 
The IFN-a/b  system is a powerful and immediate antiviral host response. It is therefore not 
surprising that many viruses have evolved mechanisms to counteract this response at every 
possible level. Viruses are able to prevent production of IFN-b  or prevent binding of IFN to 
the IFN receptor, inhibit IFN-mediated signaling and/or selectively block the activity of 
distinct ISGs (37). To prevent the stimulation of ISG expression, a virus can either block IFN-
mediated signaling or impair induction/production of IFN. In the case of BRSV, previous 
studies suggested that IFN signaling was rather not affected (J. Schlender, personal 
communication). In addition, HRSV was reported not to affect IFN signaling (108). 
Therefore, as a first step in elucidating the mechanism by which BRSV prevents upregulation 
of ISGs, we directly assayed for the presence of IFN in supernatants of cells infected with 
various recombinant BRSVs. Whereas IFN was readily detectable in supernatants of MDBK 
or HEp-2 cells infected with BRSV D1/2 or BRSV h1/2, no significant amount of IFN was 
found in BRSV wt-infected cells suggesting that in the presence of the two NS proteins, 
induction of IFN may well be inhibited (Fig. 26). To distinguish between a possible block in 
IFN induction or secretion we subsequently looked for IFN-b  gene promoter activity in 
infected cells, making use of a reporter construct expressing the luciferase gene under the 
control of the IFN-b  promoter/enhancer. While IFN-b  promoter activity increased more than 
20-fold in cells infected with BRSV D1/2, wild-type BRSV elicited only a very slight increase 
demonstrating that the NS proteins are able to block the induction of IFN-b  promoter activity 
in the course of a viral infection (Fig. 27). Moreover, infection of cells with single deletion 
mutants BRSV D1 and BRSV D2 showed that, similar to their IFN resistance function, both 
NS proteins are required for the block in IFN induction (Fig. 31). In addition, BRSV wt was 
able to inhibit the induction of IFN even in the presence of an additional trigger, namely the 
dsRNA analog poly I/C (Fig. 28) demonstrating that in the presence of the two NS proteins 
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BRSV can block an as of yet unidentified step in the IFN induction pathway. To our 
knowledge, this makes BRSV the first member of the Paramyxovirus family that does not 
induce the IFN-b gene promoter.  
 
Induction of IFN-b  expression is controlled by an enhanceosome that binds three distinct 
transcription factor complexes in the context of chromatin-organizing proteins. Each of these 
factors, IRF-3, NF-kB, and ATF/c-Jun (AP-1), becomes activated following protein 
phosphorylation events induced in response to viral infection. The virus-specific C-terminal 
phosphorylation of IRF-3 is mediated by a unique, as of yet unidentified virus activated 
kinase (VAK) activity and leads to conformational changes within the IRF-3 protein that 
enable its dimerization, nuclear translocation, association with the CBP/p300 coactivator and 
subsequent stimulation of transcriptional activities. Since paramyxoviruses are generally 
known to be potent inducers of VAK activity I investigated whether this activity was impaired 
in BRSV-infected cells by measuring the amount of phosphorylated IRF-3 available in the 
nuclei of cells shortly after viral infection. Indeed, whereas phosphorylated IRF-3 was present 
in cells infected with BRSV D1/2, BRSV h1/2 or HRSV, I was not able to detect it in wild-
type BRSV infected cells (Fig. 29). This result indicates that the two NS proteins of BRSV, 
but not of HRSV, are able to inhibit the induction of IFN-b  by preventing the activation of 
IRF-3. This finding was further supported by studies using reporter constructs expressing the 
luciferase gene under the control of either IRF-3 or NF-kB or AP-1 binding sites. Preliminary 
data suggest that whereas IRF-3 activity was greatly compromised in cells infected with 
BRSV wt compared to BRSV D1/2 infected cells, NF-kB and AP-1 activities were detectable 
in both BRSV D1/2 and wt BRSV infected cells, (Fig. 30) hinting at a selective block of IRF-
3 activity in wild-type BRSV infected cells.  
 
Surprisingly, both chimeric viruses expressing one HRSV and one BRSV NS protein, BRSV 
h1 and BRSV h2, respectively, were also able to block phosphorylation of IRF-3 (Fig. 32). It 
is tempting to speculate that this ability to block the establishment of the antiviral state may 
explain why both chimeric viruses, in contrast to BRSV h1/2, are not attenuated in bovine 
cells (Fig. 18C). Considering BRSV h1/2, we think that its attenuated growth phenotype in 
bovine cells can be explained by at least two reasons. Firstly, infection of MDBK cells with 
BRSV h1/2 elicits IFN production and the subsequent establishment of an antiviral state. 
Secondly, the HRSV NS proteins do not efficiently inhibit the bovine cellular IFN system. 
Hence, growth of BRSV h1/2 is impaired. In human cells, BRSV h1/2 infection also leads to 
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the production of IFN. However, the HRSV NS proteins are more efficient in inhibiting a 
human cellular IFN system and therefore, viral replication is not affected. The generation of 
recombinant BRSVs that lack one particular IFN antagonist function (e.g. inhibition of IFN 
induction) while keeping the other (e.g. IFN resistance) will be a useful tool to study the in 
vivo relevance of RSV IFN antagonist activity. 
 
Activation of IFN gene expression is a cellular response resulting from the innate immune 
recognition of virus infections, but how cells sense viral replication is only poorly understood. 
It is generally believed that dsRNA generated during certain steps in viral replication is the 
principal inducer of IFN. A main sensor for dsRNA seems to be the RNA-dependent protein 
kinase PKR which, upon recognition of dsRNA and a subsequent autophosphorylation step, 
activates the IKKb  subunit of the multicomponent IkB kinase eventually leading to the 
activation of NF-kB. However, PKR is not sufficient to mediate the full antiviral response 
since mice with homozygous disruptions of the PKR gene displayed normal antiviral 
responses to infection with influenza and vaccinia virus both in mice and in cells lacking PKR 
(1). Another protein able to recognize dsRNA is the Toll- like receptor 3 (TLR3) normally 
involved in the immune recognition of microbial pathogens. Upon dsRNA-mediated 
activation, the receptor was shown to induce the activation of NF-kB and production of type I 
IFNs (2). However, whether TLR3 plays a role in the host’s defence against viral infections 
remains to be established. Recently, tenOever et al. showed for the first time that direct 
recognition of a viral protein, namely the Measles virus nucleocapsid protein, resulted in 
activation of IRF-3 and subsequent induction of IFN (89). Furthermore, the nucleocapsid 
protein was found associated with both IRF-3 and VAK activity, suggesting that it may be 
used in the colocalization of the kinase and its substrate. Future studies will be aimed at 
elucidating the trigger provided by BRSV D1/2 for efficient IFN induction in infected cells 
and the molecular mechanism (and involved targets) by which the BRSV NS proteins prevent 
phosphorylation of IRF-3. Interestingly, the inhibition of IRF-3 activation to prevent IFN 
induction may be in fact more advantageous for a given virus than e.g. the inhibition of NF-
kB activation. Very recently, IRF-3 was reported to directly induce the expression of various 
ISGs via their ISRE elements in an IFN-independent manner (40) and may even be, in certain 
cells, able to induce the IFN-b  mRNA without involvment of NF-kB or ATF/c-Jun (75). 
However, whether BRSV is sensitive to ISGs directly upregulated by IRF-3 and/or whether 
these IFN-independent induction pathways have any in vivo relevance awaits further 
investigation. 
                       DISCUSSION  
     90 
Interestingly, we were recently able to show that the BRSV NS1 protein can activate the 
transcription factor NF-kB (B. Bossert, unpublished results). Activation of NF-kB is a 
mechanism employed by multiple families of viruses including HIV-1, HTLV-1, EBV and 
HCV to improve viral replication, enhance viral gene expression, and to prevent virus-
induced apoptosis. Although the molecular details remain mostly unclear, certain viral 
proteins such as the HIV-1 Tat protein, the HTLV-1 Tax protein, and EBV LMP-1 are able to 
activate NF-kB through several distinct mechanism (47). In addition, NF-kB, like IRF-3, is 
also activated by synthetic dsRNA, suggesting that viruses that generate dsRNA replicative 
intermediates share a common mechanism by which NF-kB is activated. On the other hand, 
since activation of NF-kB by infection is a key trigger for the induction of IFN-a/b , several 
viruses encode inhibitors of NF-kB activation or function (47). However, it is well established 
that NF-kB also induces antiapoptotic genes and any virus that blocks NF-kB activation may 
leave itself suceptible to enhanced induction of apoptosis. I therefore hypothesize that BRSV 
is able to inhibit the induction of IFN triggered most probably by dsRNA replicative 
intermediates at a very early step so that not only activation of IRF-3 but also activation of 
NF-kB is prevented. To avert apoptosis in infected cells, BRSV then activates NF-kB by a 
dsRNA-independent, NS1-mediated mechanism. However, I do not rule out the possibility 
that activated NF-kB may serve additional functions in the BRSV-infected cell. Future 
experiments will reveal by which mechanism NS1 activates NF-kB and how this activation 
influences the host cell to allow optimal viral replication. 
 
 
Nuclear localization of pneumovirus NS proteins  
 
Replication of RSV is believed to be accomplished entirely in the cytoplasm. Therefore, the 
nuclear localization of both BRSV NS proteins was surprising. Having generated recombinant 
BRSVs expressing tagged NS1 or NS2 genes (BRSV ha and BRSV fl, respectively), I was 
able to perform immunofluorescent studies to determine the cellular localization of the BRSV 
NS proteins. Quite unexpectedly, both proteins were not only found in the cytoplasm, 
predominantly colocalizing with inclusion bodies formed by the BRSV N, P, and M proteins, 
but also in the nucleus, yet no staining of the nucleoli was observed (Fig. 35). To rule out a 
possible staining artefact, nuclear extracts of infected cells were prepared and the presence of 
each NS protein in the nucleus was confirmed by Western blot and immunoprecipitation (data 
not shown). In subsequent immunofluorescent studies, using chimeric BRSVs expressing 
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various combinations of pneumovirus NS proteins, a similar cellular distribution was found 
for the HRSV and PVM NS proteins (Figs. 36/37). Moreover, in cells infected with rRVs 
expressing individual pneumovirus NS proteins, all three NS1 proteins showed a nuclear 
localization indicating that the pneumovirus NS1 proteins do not depend on any other 
pneumovirus protein to reach the nuclear compartment (Fig. 38). Unfortunately, we were not 
able to detect a specific signal for the BRSV and HRSV NS2 proteins in immunofluorescent 
studies when expressed by rRVs, probably due to low expression levels and/or the short half-
life reported for the HRSV NS2 protein (33). However, in cells infected with VB mNS2, 
PVM NS2 was readily detectable in the nucleus and the cytosol indicating that at least the 
PVM NS2 protein reaches the nucleus independently of another pneumovirus protein (Fig. 
38). The conservation of the cellular localization among all pneumovirus NS proteins strongly 
suggests that their presence in the nucleus of infected cells must serve an important function 
for successful viral replication. 
 
How the pneumovirus NS proteins reach the nuclear compartment is not known. Their amino 
acid sequences do not contain short stretches of basic amino acids known to function as 
nuclear localization signal (NLS) and which are believed to be recognized by importins, 
cytosolic receptor molecules that recognize and dock the NLS-containing proteins at the 
nuclear pore. In principal, the NS proteins are small enough (14-18 kD) to enter the nucleus 
via diffusion through the nuclear pore. However, when infected cells were treated with 
digitonin/Triton X-100 prior to fixation and subsequent immunostaining, the BRSV NS 
proteins and PVM NS1 were retained in the nucleus whereas the GFP protein, known to enter 
the nucleus via diffusion, was eliminated from the nuclear compartment suggesting that NS 
proteins are retained in this specific cellular compartment probably by binding to cellular 
factors (Fig. 39). Support for this hypothesis also comes from two-hybrid studies performed 
in our laboratory. Several interaction partners for the BRSV NS proteins were identified, most 
of which are nuclear proteins involved in transcriptional regulation (M. Wolff, unpublished 
results).   
 Whether the presence of the NS proteins in the nucleus is related to their function as IFN 
antagonists is not known at present. Attempts to relocate the BRSV NS1 protein to the 
cytoplasm by adding the nuclear export sequence (NES) of protein kinase I (PKI) to either 
protein terminus failed so far. However, the use of other nuclear export sequences to exclude 
the NS proteins from the nucleus is currently under investigation. The analysis of recombinant 
BRSVs expressing NS proteins that are restricted to the cytoplasmic compartment may then 
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reveal the contribution of the nuclear NS proteins to their diverse functions in the IFN 
pathway and in virus replication. 
 
 
  The frequently asked question: why two proteins? 
 
Many viruses encode one or more proteins that can act as IFN antagonists by inhibiting one or 
several steps in the cellular IFN pathway. For example, vaccinia virus encodes two proteins, 
E3L and K3L, that bind PKR and, in the case of E3L, also dsRNA thereby preventing the 
induction of IFN. In addition, poxviruses secrete soluble IFN-a/b  receptors that bind and 
sequester IFNs (37). However, each IFN antagonistic protein encoded by vaccinia or any 
other virus was found to function individually in blocking the cellular IFN system. Therefore, 
the finding that – in the case of BRSV – two viral proteins have to obligatorily cooperate to 
block the induction of IFN or mediate resistance to IFN-induced responses is unprecedented 
and intriguing.  
 
How do the NS proteins accomplish their IFN antagonist functions? The HRSV NS2 protein 
was reported to form dimers and, possibly, tri- and tetramers in infected cells (33). Moreover, 
two-hybrid-studies performed in our laboratory showed that the BRSV NS proteins can form 
homo- and heterodimers (M. Wolff, unpublished results). Moreover, the BRSV NS proteins 
were able to interact with any HRSV NS protein whereas the PVM NS proteins did not 
interact with each other or with any other pneumovirus NS protein (M. Wolff, unpublished 
results). Interestingly, heterologous NS protein pairs from HRSV and BRSV that interact in 
two-hybrid-studies were also found functional in confering IFN resistance whereas 
combinations of PVM and BRSV NS proteins that do not interact (and are therefore not able 
to cooperate?) cannot mediate resistance to IFN. In view of these data we are tempted to 
postulate a heterodimer consisting of NS1 and NS2 proteins (NS1-NS2 or combinations 
thereof like e.g. NS1-NS2-NS2) as the active IFN antagonist activity that targets cellular IFN 
pathway proteins. That both NS proteins act together to block the IFN system rather than 
individually target cellular proteins is also supported by the finding that single expressed NS 
proteins do not show any IFN antagonistic activity. However, we do not rule out that the NS 
proteins can also have separate functions with individual targets. For example, the NS1 
protein of HRSV was shown to bind the RSV matrix protein whereas for the NS2 protein no 
viral interaction partner was found (33) suggesting a function for the NS1 protein in viral 
replication. However, deletion of either NS protein from the BRSV genome results in similar 
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attenuation phenotypes (80) indicating that also for viral replication, the presence of both NS 
proteins is required. Interestingly, we were recently able to show that the BRSV NS1 protein 
can activate the transcription factor NF-kB whereas expression of NS2 had no effect 
demonstrating for the first time a separate function for one of the NS proteins (B. Bossert, 
unpublished results). Future studies aimed at elucidating the molecular mechanisms involved 
in the manifold functions of the NS proteins such as IFN antagonist activity and a possible 
effect on cellular transcription will give more insight into how the NS proteins shape the 
cellular environment of their host for the benefit of efficient viral replication. 
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SUMMARY 
 
Bovine respiratory syncytial virus (BRSV), a member of the Paramyxoviridae family, 
subfamily Pneumovirinae, is a major etiological agent of respiratory tract disease in calves 
(92). A peculiarity of pneumoviruses is the presence of two unique nonstructural (NS) protein 
genes, NS1 and NS2. Due to their 3’ proximal location on the genome, the NS genes are 
abundantly transcribed. To determine the role of the NS proteins in the viral life cycle, BRSV 
deletion mutants that lack either one or both NS genes have been generated (8,80). Growth of 
all NS deletion mutants was severely impeded in IFN-producing cells, and subsequent studies 
identified type I IFNs as the host cell factors responsible (80). Interestingly, the addition of 
exogenous type I IFN suppressed growth of all three NS deletion mutants equally whereas wt 
BRSV was not affected. This suggested that the presence of both NS proteins is required for 
resistance of BRSV to IFN. 
By using recombinant rabies viruses (RVs) expressing either NS gene I was able to 
show that only in cells co- infected with NS1- and NS2-expressing RVs, virus replication was 
resistant to exogenous IFN (80). Thus, the BRSV NS proteins have the potential to 
cooperatively protect an unrelated virus from IFN type I mediated cellular antiviral responses 
independent of other viral functions provided by BRSV. In similar experiments, the 
nonstructural proteins of two other pneumoviruses, human respiratory syncytial virus (HRSV) 
and Pneumovirus of Mice (PVM), were also able to enhance IFN resistance of RV suggesting 
that pneumoviruses share a common IFN resistance mechanism mediated by their unique NS1 
and NS2 proteins. Furthermore, by employing chimeric BRSVs carrying heterologous NS 
genes, the pneumovirus NS proteins were shown to act as host range determinants by 
counteracting cellular innate responses in a host cell-specific manner, and confering IFN 
resistance most actively in cells derived from their natural host (7). 
  
Production of type I IFNs in response to viral infection is one of the main defense 
mechanisms of the innate immune system leading to the establishment of a cellular antiviral 
state. Indeed, infection of cells with the NS deletion mutant BRSV D1/2 highly stimulated 
IFN-b  gene promoter activity leading to upregulated expression of IFN-stimulated genes 
(ISGs). However, the presence of both NS proteins in wt BRSV-infected cells prevented this 
virus- induced activation of the IFN-b  gene promoter. Moreover, the inhibitory effect of the 
BRSV NS proteins on IFN-b  induction was not overcome by the addition of a known IFN 
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inducer, the dsRNA analog poly I/C. Of the three transcription factors required for activation 
of IFN-b  gene expression, NF-kB, AP-1, and IRF-3, the activation of IRF-3 was prevented in 
BRSV wt infected cells. These results indicate that in the presence of both BRSV NS 
proteins, inhibition of virus- induced IFN induction is achieved by the selective block of IRF-3 
activation, thus preventing production of IFN-b  and the subsequent stimulation of IFN 
responsive genes.  
 
The BRSV NS proteins are thus able to interfere with the cellular immune response at two 
different levels. Firstly, IFN-b  induction is prevented by selectively blocking virus- induced 
IRF-3 activation. Secondly, the NS proteins are able to mediate viral resistance to exogenous 
IFN. This knowledge on NS protein function and the possibility to generate stable 
recombinant RSVs with adjustable IFN escape capacities have important implications for the 
development of live-attenuated RSV vaccines. 
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